DEPARTMENT OF
Biomedical Engineering
UNIVERSITY OF WISCONSIN–MADISON

CRISPRi Screening in Cancer Spheroids to Investigate Factors in Genome Stability

Preliminary Report
BME 400: Biomedical Engineering Design
October 14, 2024

Team Members:

Althys Cao (Leader)

Ana Martinez (Communicator)

Emily Rhine (BSAC)

Julia Salita (BWIG)

Jayson O'Halloran (BPAG)

Client:

Ms. Carley Schwartz, Biomolecular Chemistry

Dr. Gaelen Hess, Department of Biomolecular Chemistry and

Center for Human Genomics and Precision Medicine

Advisor:

Dr. Paul Campangnola, Department of Biomedical Engineering, Peter Tong Department Chair

Abstract:

The objective of this project is to develop a three-dimensional (3D) cell culture model compatible with CRISPR interference (CRISPRi) screening to identify sources of DNA damage and mutations in cancer. Traditional two-dimensional (2D) models have limited biological relevance, often failing to replicate the complex interactions found in vivo. By establishing optimized protocols for spheroid formation using a suitable human lung cancer cell line, the team aims to create a more accurate representation of the tumor microenvironment.

A key aspect to this project is the implementation of γH2AX staining as a sensitive marker for DNA double-strand breaks (DSBs), allowing for precise quantification of DNA damage within the spheroids. Through high-throughput genome-wide CRISPR screening, the team will assess the effects of various genes on γH2AX levels, enhancing the understanding of the molecular mechanisms underlying cancer progression.

By bridging the gap between in vitro studies and clinical applications the team hopes to provide valuable insights that could lead to more effective cancer therapies and improved patient outcomes. By mimicking the 3D tumor environment, the pathways involved in DNA damage response are more tailored to what is actually seen in oncogenesis, providing new avenues for remedial intervention in cancer treatment.

Table of Contents:

1. Introduction
1.1. *Motivation and Societal impact*
Cancer affects millions each year with an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States, in 2022 [1], and not mentioning those still living with cancer. In the past, using 2D monolayer with CRISPR screening has provided extensive knowledge on what drives cancer cell high growth rate and what therapeutic treatments they are susceptible to. However, it fails to accurately represent the 3D tumor environment, leaving out important factors such as genome stability and DNA damage regulatory genes. Providing a replicated 3D tumor environment that is compatible with CRISPR screening can help identify sources of DNA damage not found with 2D cultures. This can lead to early detection, new therapeutic tools, and possibly genomic therapies.

1.2. *Problem Statement*
Although previous CRISPR screening in 2D monolayers has provided useful knowledge on cancer drivers and therapeutic susceptibilities, it lacks an element of biological relevance to an in vivo environment. Therefore, our team was tasked with developing a cell culture method that is compatible with a 3D environment and CRISPRi screening in order to identify sources of DNA mutations in the tumor environment. To achieve this goal, the team must select a viable cell line for the screen, create and optimize a spheroid formation protocol, and develop a protocol to stain for γH2AX: a histone variant that is a sensitive marker for DNA damage.

2. Background
2.1. *Background Research*
2.1.a. *3D spheroids*
The study of cancer and its progression has evolved significantly, with advancements in genetic and molecular biology providing deeper insights into the mechanisms underlying tumorigenesis. In this context, 3D spheroids have emerged as a superior model compared to traditional 2D monolayer cultures. 2D cultures are limited in their ability to replicate the complex cellular interactions and microenvironment characteristic of actual tumors, which can lead to misleading results in drug response and tumor behavior studies [2]. In contrast, 3D spheroids, composed of cancer cells aggregated in a spherical configuration, better mimic the architecture and growth phenotypes observed in tumors as seen in Figure 1 [2]. This structural arrangement facilitates critical cell-cell and cell-matrix interactions, which are essential for maintaining cellular functions and responses to therapeutic agents [3]. Consequently, the use of 3D spheroids enhances the fidelity of experimental models, allowing for a more accurate investigation of tumor biology, cancer progression, and the efficacy of potential treatments.

Figure 1: Comparison of 2D versus 3D tissue culture [4].

2.1.b. *Cell line*

Creating a cancer cell line is a multifaceted process that begins with the collection of tumor tissue from a cancer patient, typically obtained through biopsy or surgical resection. Once the tissue is collected, it undergoes processing to isolate individual cancer cells, often involving enzymatic digestion or mechanical disruption to break down the extracellular matrix and liberate the cells [5]. These isolated cells are then placed in a nutrient-rich culture medium designed to support their growth, containing essential nutrients, growth factors, and an appropriate pH. As the cells proliferate, certain cancer cells may demonstrate faster growth rates; these cells can be selected for further cultivation. Once cultivated, a cell line is then defined as continuous (infinite) or finite. For the purposes of this design project, both infinite and finite cell lines have been considered. After establishing a stable culture, the cell line undergoes thorough characterization to confirm its cancerous properties, assessing factors such as cell morphology, growth rate, and genetic markers. Finally, once a stable and well-characterized cell line is established, it is cryopreserved in liquid nitrogen for long-term storage [6]. The cell lines considered must be able to display a 3D tumor environment upon spheroid formation, be compatible with CRISPRi screening, and express γH2AX.

Figure X: Cell line creation [5].

2.1.c. *CRISPRi Screening*

CRISPR interference (CRISPRi) is a powerful tool for gene regulation that allows for the targeted repression of gene expression without directly inducing double-strand breaks in the DNA. This technique utilizes a catalytically inactive Cas9 (dCas9) protein fused to transcriptional repressors, enabling precise control over gene activity [7]. In this project, lentiviral vectors are employed to deliver the CRISPRi components into the target human lung cancer cell lines, such as A549 and NCI-H23. The use of lentivirus is advantageous due to its ability to efficiently transduce a wide range of dividing and non-dividing cells, ensuring stable expression of the dCas9 and guide RNA (sgRNA) constructs necessary for effective gene repression [7]. By applying CRISPRi in a 3D spheroid model, the team's design aims to better mimic the in vivo tumor microenvironment for the screen, which is essential for understanding the complex interactions that drive cancer progression and treatment resistance. This approach facilitates the identification of gene targets that contribute to DNA damage responses and cellular survival in a more physiologically relevant context compared to traditional 2D cultures.

2.1.d. *γH2AX*

γH2AX is a phosphorylated variant of the histone H2AX, which serves as a sensitive marker for DNA double-strand breaks (DSBs) [2]. The phosphorylation of H2AX occurs rapidly in response to DNA damage, making it an essential marker for monitoring the integrity of the genome [3]. In cancer research, γH2AX staining is utilized to assess the extent of DNA damage and the efficacy of DNA repair mechanisms. In the team's model, γH2AX allows for the quantification of DNA damage induced by various genetic modifications and treatments within the 3D spheroid model. This is particularly relevant in the context of CRISPRi screening, where the identification of genes that influence DNA damage response pathways can provide insights into tumor biology and therapeutic vulnerabilities. By utilizing γH2AX as a biomarker, the team

can effectively evaluate how specific gene targets contribute to genomic stability and cancer progression.

It is important to choose a cell line that has been proven to be sensitive (or has a baseline of sensitivity) to DNA damage for successful γH2AX staining. One way to determine this criteria is to see whether that cell line is sensitive to drugs that can induce DNA damage. The drugs chosen for this purpose include cisplatin, oxaliplatin, and bleomycin.

Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various solid tumors, including lung, ovarian, and bladder cancers. Its mechanism involves the formation of DNA cross-links, which interfere with DNA replication and transcription, leading to cell cycle arrest and apoptosis [8]. Another platinum-based compound with similar anticancer mechanisms is oxaliplatin, which is more effective in some forms of cancer such as colorectal cancer [9]. On the other hand, bleomycin, an antitumor antibiotic, induces DNA damage through the generation of free radicals, leading to both single and double-strand DNA breaks. Unlike platinum-based drugs, bleomycin's mechanism of action makes it suitable for combination therapy, targeting cancer cells through a different pathway [10].

Drug sensitivity is quantitatively measured by Z-score, which measures drug sensitivity of a specific cell line to a specific drug in comparison to other cell lines. Negative Z-scores reflect sensitivity, with lower values indicating greater susceptibility to the drug's cytotoxic effects, while positive Z-scores indicate resistance [11]. A Z-Score of ±1 is considered significant [12]. These differential responses across cancer types and drug classes highlight the complexity of cancer treatment and the need for tailored therapeutic approaches based on specific tumor characteristics.

2.1.e. *Previous Literature*

In previous research, 3D cancer spheroid models have been utilized for CRISPR-Cas9 screens with and without using an exogenous extracellular matrix (ECM).

Takahashi *et al*, 2020 utilized 4% Matrigel, an ECM based approach, as bio-scaffolding to plate A549 and H1437 cells spheroids. They concluded that their seeded spheroid models *in-vivo* interactions between cells and the ECM were more biologically relevant than former 2D studies [13]. The study's CRISPRi library gene list as well as its phenotypes have a strong overlap with those from Han *et al*, 2020, suggesting that inner cells of ECM-based 3D spheroids may be similar to ECM-free 3D spheroids.

Han *et al*, 2020 devised an ECM-free scalable method to propagate 3D spheroids [14]. H23 cells were seeded on pre-treated ultra-low attachment or polyhema-covered plates in RPMI 1640 medium with 0.75% methylcellulose. Similar methods have been found to be implemented in other studies, such as by Ferrarone, *et al* (2024) and by Stiff, *et al* (2024) [15], [16]. A total of around 210,000 single guide RNAs (sgRNAs) were designed for the CRISPRi library with around 10 sgRNAs per gene [14]. Samples were used to calculate growth and/or tested for drug resistance [14].

3D stem cell models have also been genomically edited via CRISPR-Cas9 to better model various disease phenotypes. Cells can be assembled with or without supporting scaffolds. Some example scaffolds include laminin-rich Matrigel, collagen matrix, or those that are naturally derived from decellularized tissues [17].

2.2. *Client Information*

The clients, Ms. Carley Schwartz and Dr. Gaelen Hess are researchers at the Hess Laboratory within the Wisconsin Institutes for Medical Research (WIMR). The group's research focus is on high-throughput functional genomics to investigate DNA repair and pathogenic effectors [18]. Dr. Hess is an assistant professor in the Department of Biomolecular Chemistry and Center for Human Genomics and Precision Medicine [18]. Ms. Carley Schwartz is the lab manager and a research intern at the Hess Laboratory.

2.3. *Design Specifications*

The project aims to develop a 3D cell culture method compatible with CRISPRi screening to identify sources of DNA mutations in tumors, utilizing γH2AX as a marker for DNA damage. The client requires the team to select an appropriate human lung cancer cell line, to which A549 and NCI-H23 meet that criteria [19]. This protocol must focus on optimal seeding density, targeted at 50,000 cells/cm², and viscosity adjustments through methylcellulose to ensure uniform spheroid size and maximal cell growth [14]. Additionally, a γH2AX staining protocol needs to be established following the guidelines of scalability, and be reproducible with optimized antibody concentrations and reagent volumes.

With the use of human contaminants, safety measures are to adhere to all Biosafety Level 2 (BSL-2) standards, implementing containment protocols and proper waste disposal [20]. The accuracy and reliability of the spheroid formation process will be monitored through live-cell imaging to confirm a ~30% cell death rate, and at least three staining experiments will be conducted to establish statistical confidence in the results.

For life in service, cells will require approximately two months in culture for protocol optimization, followed by a minimum of six days post-infection with the CRISPRi library and 21 days for spheroid maturation. To ensure long-term viability, cells will be cryopreserved at temperatures below -135°C. Operating conditions will be maintained at 37°C, 5% CO_2, and 90–95% humidity [21].

The design will prioritize ergonomic efficiency in the experimental setup, aiming to enhance throughput while accurately mimicking in vivo conditions. Spheroids are targeted to be ~500 μm in diameter, and accurate assessments of mass and density will be facilitated through specialized equipment [22]. The project budget is capped at $1,000, with a focus on utilizing existing lab materials to keep costs manageable.

Lastly, the team will conduct a competitive analysis of existing 3D cancer models, focusing on methodologies that incorporate ECM-free approaches. Key milestones include cell line creation and protocol development by October 2024, optimization of spheroid formation by

November 2024, completion of the γH2AX staining protocol by December 2024, execution of high-throughput CRISPR screening by February 2025, followed by analysis of phenotypic differences before May 2025.

3. Preliminary Designs

3.1. Cell Lines

3.1.a. <u>NCI-H23</u>

NCI-H23 is an epithelial-like cell that was isolated from the lung of a Black, 51-year-old, male patient with adenocarcinoma. H23 is a non-small cell lung cancer (NSCLC) with a doubling time 38 hours [23]. Although H23 is considered an adherent cell line, it is known to have weaker cell-cell interactions due to the lack of E-cadherin at the cell membrane [24]. H23 exhibits TP53, KRAS-12, epidermal growth factor receptor (EGFR), L-dopa decarboxylase-negative, and a high degree of c-myc DNA amplification (20-fold) but no detectable amplification of c-myc RNA [23]. Additionally, these cells have a reported colony forming efficiency of 9.7% in soft agarose [2]. H23 is very sensitive to bleomycin (Z-score average of -1.22), somewhat sensitive to cisplatin (-0.73), and somewhat resistant to oxaliplatin (+0.41) [25]. One vial of these cells from ATCC is $555.00 [23].

3.1.b. <u>A549</u>

A549 is an adherent cell line isolated from the lung tissue of a White, 58-year-old male with lung cancer [26]. This NSCLC carcinoma has a doubling time of 22 hours [26]. A549 exhibits mutations for TP53, EGFR, PIK3CA, ALK, and PTEN [27]. A549 is very sensitive to bleomycin (Z-score average of -1.04), somewhat sensitive to cisplatin (-0.12), and very sensitive to oxaliplatin (-1.45) . One vial of these cells from ATCC is $555.00 [26].

3.1.c. <u>OVCAR-5</u>

OVCAR-5 is a cell line established from ascites fluid from a 67 year old non-treated patient with a metastatic gastrointestinal cancer that has presented as advanced-stage ovarian carcinoma [28]. The doubling time for this cell line is 27 hours [29]. OVCAR-5 expresses mutations for KRAS-12, EGFR, and CLAUDIN-4 [28]. This ovarian cancer cell line is somewhat resistant to bleomycin (Z-score average of +0.67), somewhat resistant to cisplatin (+0.52), and somewhat sensitive to oxaliplatin (-0.18) [30]. This cell line is not currently available for the team to purchase [28], [31].

3.2. Spheroid Formation Protocol

3.2.a. <u>Treated Tissue Culture Plates</u>

Treated tissue cultures method is a scaffold-free method [32]. It uses low attachment plates, which are coated with a hydrophilic polymer (such as hydrogel or poly-HEMA) to prevent specific and nonspecific cell adhesion to the culture vessel [32]. Thus, high cell-to-cell interactions allow cells to cluster together, form cell aggregates and eventually into 3D spheroids (Figure 3) [33]. The number and size of spheroids formed depend on the shape of the wells, with

U-bottom wells creating a single and well-defined spheroid for each well (Figure 3) [33]. The whole process usually takes up to 4 days [33].

Figure 3: Spheroid formation by treated tissue culture plates/low attachment plates with U-bottom wells (left) and flat-bottom (right) [32].

3.2.b. *Hanging Drop*

Similar to the treated tissue cultures method, the hanging drop method is also anchorage-independent [32]. Currently, two methods to form hanging drops exist. The first method is the traditional method, involving dispensing small amounts of cell suspension on a surface, usually the underside of a petri dish, then flipping the dish upside down to form hanging drops (Figure 4) [34]. However, this method has a high risk of droplet fusion (if space is limited), loss of droplet shape (because of frequent media change), and droplet evaporation [35], [36]. The second method using hanging drop plates negates these risks [36]. Each plate consists of a lid to maintain sterility and a main component, which has a water reservoir to prevent evaporation and access holes on top where cells can be added to form hanging drops on the bottom (Figure 5a) [36]. Hanging drops create a flexible spheroid cell-to-liquid interface, allowing cells to gravitationally aggregate and form because of high cell-to-cell interactions (Figure 5b) [32]. The whole process usually takes up to 4 days [33].

Figure 4: Spheroid formation by flipped hanging drop method [34].

Figure 5: Spheroid formation by hanging drop plate [32].
a. Composition of a hanging drop plate, b. Spheroid formation.

3.2.c. _Matrigel_

The Matrigel method is a scaffold-dependent method [32]. Cells are cultured in low attachment plates for 4 days to form aggregates, then Matrigel is added to encourage cell-to-ECM interactions which will form spheroids after another 2 days (Figure 6) [37].

Figure 6: Comparison of single 3D spheroids grown without and with Matrigel [38]. Green indicates live cells and red indicates dead cells.

4. Preliminary Design Evaluation

4.1. Design Matrix for Cell Line

Table 1. Design matrix for Cell Line.

Design Criteria (weight)	NCI-H23		A549		OVCAR-5	
	Score X/5	Weighted score	Score X/5	Weighted score	Score X/5	Weighted score
Viability (20)	4	16	5	20	3	12
Adhesion (20)	3	12	4	16	4	16
Reproduction Speed (20)	3	12	5	20	4	16
Drug Sensitivity (15)	4	12	5	15	3	9
Genetic Mutation (15)	5	15	3	9	2	6
Ease of Procurement (10)	5	10	5	10	5	10

Total Score (100)	77	90	69

Determination of Criteria and Weights & Justification of Assigned Scores: After discussion about the important criteria to evaluate the initial designs against our Product Design Specifications, the following categories were chosen.

Viability (20):

Cell viability is a measure of the proportion of live, healthy cells within a population [39]. For this category, viability is a measure of how robust the cell is and how well it can withstand various stresses. The highest ranked cell line is predicted to be the healthiest after fluid shear stress, transfection, and cisplatin treatment.

NCI-H23 cells were assigned a score of 4/5 for its and >20% cell death after 72 hours when subjected to [3 μM] of cisplatin and its sensitivity to cisplatin treatment [40]. The NCI H23 cell line showed a higher expression level of DNA repair proteins after cisplatin treatment compared to A549 cells. In previous experiments for both NCI-H23 and A549, a negative correlation between cell viability and DNA damage induction upon cisplatin treatment has been noted [40]. A549 cells were assigned a score of 5/5 for its >20% cell death after 72 hours when subjected to [3 μM] of cisplatin and its greater resistance to cisplatin treatment compared to NCI-H23 cells [40]. OVCAR-5 scored a 3/5 for its severe morphological changes (decreased spheroid-forming capacity, reduced cytoskeleton organization, and chromosomal instability) after exposure to <1 dyne/cm^2 fluid shear stress and >50% cell death after 72 hours when subjected to [2.5 μM] cisplatin [41], [42].

The type of transfection done to these three cell types may either help or hinder the cell health depending on the transfection virus used (lentivirus or siRNA)and what it is used in conjunction with (Nrf2, cisplatin, or both). The trend in scientific literature indicates that these three cell types have the same viability, within 7±3%, when transfected under the same conditions [40], [41], [42]. Since the vectors encoding the components necessary for CRISPR/Cas are large, they result in low transfection efficiency and cell viability [43]. To overcome those obstacles, the team can add exogenous small plasmids that increase transfection efficiency up to 40-fold and cell viability up to 6-fold [43].

Adhesion (20):

This criteria refers to the ability of cells to attach to the surface of the culture vessel or substrate they are grown in, as well as to attach to other cells. For this criteria, cell lines were therefore judged on whether they were considered an adherent cell line and on their strength of cell-cell interactions. Because adhesion is an important factor in cells being able to effectively form spheroids, this criteria was given a high weight for scoring.

Although NCI-H23 is considered an adherent cell line [23], it is known to have weaker cell-cell interactions due to the lack of E-cadherin at the cell membrane [44]. Additionally,

NCI-H23 has presented difficulty in forming spheroids in previous literature, particularly using the Matrigel method [24]. For these reasons, NCI-H23 scored 3/5. Similarly, although A549 and OVCAR-5 are considered adherent cell lines [26], [45], [46], it is also known to have a lack of E-cadherin and thus weaker cell-cell interactions [44], [47]; thus, A549 and OVCAR-5 scored 4/5.

Reproduction Speed (20):

Reproduction Speed is the time it takes the cells to grow and reproduce. In order to look specifically at the cell line, and exclude any factors caused by the spheroid formation protocol, the team used the cell lines' doubling speed. The doubling speed is the amount of time it takes for a cell population to double in number. Essentially, it is how quickly a cell line replicates itself in culture [48].

As each cell line has a range of doubling times depending on the culture medium used, the most typical doubling times were used to determine this category's score. With the longest doubling time of about 38 hours [23], [49], NCI-H23 scored the lowest at a 3/5. A549 is the fastest of the three cell lines with a typical doubling time of about 22 hours [26], [49], scoring a 4/5. Lastly, OVCAR5 has a doubling time of 27 hours [29], [49] scoring a 4/5.

Drug Sensitivity (15):

Gamma-H2AX foci staining is used for this project to assess the extent of CRISPR-Cas9-based DNA damage. Cell lines that are particularly sensitive to drugs that induce DNA damage will have a baseline of DNA damage to refer to, making them appropriate for this project.

Z-scores for NCI-H23, A549, and OVCAR-5 are obtained from the Genomics of Drug Sensitivity in Cancer Project [50]. NCI-H23 has a Z-score average of -1.22 for bleomycin, -0.73 for cisplatin and +0.41 for oxaliplatin [25]. A549 has a Z-score average of -1.04 for bleomycin, -0.12 for cisplatin, and -1.45 for oxaliplatin [51]. OVCAR-5 has a Z-score average of +0.67 for bleomycin, +0.52 for cisplatin, and -0.18 for oxaliplatin [30]. A549 has 2 significant negative Z-scores, scoring a 5/5. NCI-H23 has a negative Z-score for 1 of the drugs, scoring a 4/5. OVCAR-5 has none, scoring a 3/5.

Genetic Mutation (15):

Analysis of genetic mutations inherent to various cell lines is crucial in determining the ideal cell line for our project. A high score in this category means genetic mutations that are helpful must work with for any step in the adhesion process, Cas9 attachment, CRISPR edit, or screen. Using Han's ten selected lung cancer cell lines, a set of ideal cell line mutations were created including: TP53 (tumor protein p53), a gene that encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains [52]; EGFR, a cell surface protein that binds to epidermal growth factor leading to cell proliferation [53]; and KRAS, Kirsten rat sarcoma viral oncogene homolog causes malignancies based on an error

encoding a protein that is a member of the small GTPase superfamily [54]. These mutations may either cause or enhance the malignancy of existing cancer cells. Since TP53 is the most frequently mutated gene in human cancer, the presence of this mutation is crucial for biological relevance to half of all cancer cases [55].

NCI-H23 has all of the key mutations including TP53, KRAS, EGFR, a high degree of c-myc DNA amplification, and no counterproductive mutations, so it was given the highest score of 5/5 [23]. A549 scored second highest with 3/5 because it contains EGFR and TP53 which are key, but also PIK3CA, ALK, and PTEN which aren't key but won't impede the success of the project [27]. The protein encoded by PIK3CA, phosphatidylinositol 3-kinase, is oncogenic and represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2 [56]. ALK, anaplastic lymphoma receptor tyrosine kinase, a chromosomal rearrangement which results in creation of multiple fusion genes in tumorigenesis. PTEN guards the genome by controlling multiple processes of chromosome inheritance [57]. Although OVCAR-5 has KRAS, a key mutation, it was ranked the lowest at 2/5 due to the lack of essential protein TP53 and the presence of additional mutation CLDN4, which is a mutation of integral membrane proteins [28], [58], [59].

Ease of Procurement (10):

This criteria assesses how easy it is to obtain the cell line. It is expensive to purchase an entirely new cell line from ATCC, Sigma-Aldrich or similar sources. Therefore, the chosen cell line should be either already available in Hess Lab or can be obtained from other labs, preferably within Wisconsin Institutes for Medical Research (WIMR); however, that process can be time-consuming.

All 3 chosen cell lines are readily available in Hess Lab, both wild-type and genetically-modified, and therefore all scored a 5/5.

4.2. Design Matrix for Spheroid Formation

Table 2. Design matrix for Spheroid formation.

Design Criteria (weight)	Treated Tissue Culture Plates		Hanging Drop		Matrigel	
	Score X/5	Weighted score	Score X/5	Weighted score	Score X/5	Weighted score
Ease of Fabrication (30)	5	30	4	24	3	18
Scalability (20)	4	16	3	12	5	20
Uniform properties (20)	4	16	3	12	2	8
Cost (15)	3	9	4	12	2	6
Safety (15)	5	15	5	15	5	15
Total Score (100)	86		75		67	

Determination of Criteria and Weights & Justification of Assigned Scores: After discussion about the important criteria to evaluate the initial designs against our Product Design Specifications, the following categories were chosen.

Ease of Fabrication (30):

This criteria assesses the complexity of the 3D spheroid formation protocol, which is one of the important factors when choosing an appropriate fit-for-purpose 3D culture model [60]. Specifically, this criteria assesses whether additional specialized training or equipment will be needed for the protocol, on top of those necessary for 2D traditional cell culture methods. Also, the time needed to complete the protocol once will also be considered, as it can directly affect the length of the project due to the large number of cells needed for genome-wide CRISPR screening.

Treated tissue culture plates method scores a 5/5 as the cell seeding method is not particularly labor-intensive, only requires 1 media change and takes the least time (up to 4 days). Hanging drop method also takes the same amount of time but the cell seeding method requires more careful technique to ensure hanging drop viability and daily media change, thus scoring a 4/5. The Matrigel method does not require extensive cell seeding technique and daily media change but requires longer time (6 days), scoring a 3/5.

Scalability (20):

This criteria assesses the plausibility to use these methods to generate a large amount of viable spheroids. A high-throughput method is preferred because, per the client, each CRISPR screen would require 100-150 million cells per replicate to generate a sufficient amount of spheroids [14]. Because a high-throughput method is very important to successfully completing a spheroid CRISPR screen, this criteria was given a high weight for scoring.

The treated tissue culture plates method is known for its high-throughput capabilities because treated plates have a non-adherent coating that promotes rapid cell aggregation into spheroids [61]. This method also allows for a greater amount of spheroids to be made in a single plate because it can accommodate large volumes of media [62]. For these reasons, this method was given a score of 4/5 for scalability. The Hanging Drop method, in contrast, is considered to be low-throughput in nature. One reason for this is because the method requires a lot of manual handling and is prone to error when setting up and transferring the drops [63]. Additionally, scalability is limited with the Hanging Drop method because each tissue culture plate can only hold a limited amount of drops, and each drop only tends to form one spheroid [35]. For these reasons, this method was given a score of 3/5 for scalability. Lastly, the Matrigel method is considered high-throughput because, like the treated tissue culture plates method, it can allow for a comparatively larger volume of media to generate spheroids compared to the Hanging Drop method. Additionally, this method involves polymerizing a layer of Matrigel matrix onto tissue culture plates to promote spheroid formation [24], and unlike the other two methods, has been shown to improve the growing environment of spheroids due to its mimicry of in-vivo tumor conditions [38]. For these reasons, this method was given a score of 5/5 for scalability.

Uniform Properties (20):

This criteria outlines the reliability of the spheroid formation to produce uniform properties. The ideal formation protocol has no batch-to-batch variability. Minimal variation in size, shape, and porosity is expected so the experiment will have a higher chance of reproducibility and fewer outliers. It is important to note that research has shown that differences in spheroid formation arise from the differences in cell-biomaterial interactions rather than due to differences in cell viability or proliferation [64].

The treated tissue culture plates scored the highest in this category, 4/5, due to their minimal variation between batches. Additionally, treated tissue culture plates have a larger amount of spheroids per batch (see *Scalability* section), making it easier to harvest a uniform size or shape [60]. Due to the low-throughput nature of Hanging Drop, making it harder to harvest uniform spheroids, and due to its 10% to 15% size variation between drops, this method scored a 3/5 [65]. Matrigel, animal-based basement membrane extract, has a batch-to-batch variation that can hinder reproducibility, so a score of 2/5 was assigned to it [64]. Cells seeded in matrigel also

tend to form large cell aggregates with looser morphology rather than spheroids with round, regular shape [64].

Cost (15):

This category is scored based on the expenses of the materials needed to perform the spheroid formation protocol. While the client stressed the importance of a working protocol they also expressed their desire to keep costs to a minimum, as to be able to repeat the protocol and perform it on a larger scale.

Explain scoring:

Treated tissue culture plates scored a 3/5 in this category. Generally, the culture plates range from $0.22-3.78 per well [66], with a need for an abundance of wells. The cost of treated tissue culture plates can vary depending on the manufacturer, the number of wells needed, and the volume of cell culture media required. The Hanging Drop method is rather inexpensive as it does not require specialized equipment or reagents. At around $4 [67], [68] per 100 mm plate the Hanging Drop method is the most cost effective method out of all the options and scored a 4/5 [69]. Lastly, Matrigel scored a 2/5 in this category as the Matrigel itself is rather expensive, at $380 for 10 mL of Matrigel [64], [70].

Safety (15):

This criteria assesses the ability of the method to be used in a laboratory environment without posing significant health risks to the user or the experimental results. This includes evaluating the potential hazards associated with the materials/reagents and processes used, the ease of handling, and the effectiveness of protective measures (e.g., PPE, ventilation). A method should be dependable, minimizing the risk of contamination or adverse effects that could compromise the safety of the personnel and the integrity of the experiments.

All of the methods proposed were able to obtain a 5. This is due to none of the methods using harmful reagents in the process of fabrication. All of the cell lines pose similar contamination risk but can be lowered considerably with proper PPE use.

4.3. Proposed Final Design

A549 was the cell line selected based on the team's decision matrix (Table 1). A549 is an adherent cell line which exhibits the most useful mutations (EGFR, TP53, PIK3CA, ALK, and PTEN) [26], [27]. Since this cell line has a doubling time of approximately 22 hours, the team will need to passage the cells 2-3 times a week [71]. Hess lab recommends a maximum of 20 passages be done on each cell line, so, once thawed, each cell line will have approximately 7 weeks before it must be bleached and another cell line thawed [71].

Treated tissue culture plates, or low attachment plates method was the selected spheroid formation protocol selected based on the team's decision matrix (Table 2). The process includes using hydrophilic polymer-coated plates [32], which are not labor intensive to make, and

spheroid formation takes around 4 days [33], which is not time-consuming. Furthermore, as this method does not require a scaffold, it does not run the risk of high batch-to-batch variability due to using animal-derived matrices [32].

5. Development Process
5.1. Materials

Table 3. Estimated materials list. Materials listed are required for culturing and passaging A549 cells and are already available in Hess Lab and thus require no purchasing. Furthermore, quantities of materials are not specifically known as of now due to the nature of research but will be recorded in detail for the end of this project. To estimate, one 1 mL cryovial of A549 can be used up to 20 passages and 3 passages will be performed for each week of the project.

Material	Part Specification	Quantity	Price
T-75 Flasks	Catalog #156800 - Thermo Fisher Scientific	1 for up to 20 passages	$381.65 / case of 100 [72]
A549	CCL-185 - ATCC	N/A	$555 / vial [26]
DMEM (high glucose, no glutamine)	Catalog #11960069 - Thermo Fisher Scientific	10 mL / passage (used in solution with Pen/Strep and FBS)	$242.65 / 10 x 500 mL [73]
Penicillin streptomycin (Pen/Strep)	Catalog #15070063 - Thermo Fisher Scientific	1% in solution with DMEM and FBS	$23.65 / 100 mL of 5,000 U/mL [74]
Fetal Bovine Serum (FBS),Value	Catalog #A5256701 - Thermo Fisher Scientific	10% in solution with DMEM and Pen/Strep	$314.37 / 500 mL [75]
PBS, pH 7.4	Catalog #10010072 - Thermo Fisher Scientific	2 mL / passage	$244.00 / 6 x 1000 mL [76]
Trypsin-EDTA (0.25%)	Catalog #25200114 - Thermo Fisher Scientific	2 mL / passage	$315 / 20 x 100 mL [67]

5.2. Methods
5.2.a. *Spheroid formation protocol*

Spheroid formation protocol is based on Han *et al,* 2020 [14] and may be modified to better suit this project's needs. Cells will first be seeded at multiple densities. Cell growth and death rates will be monitored using an automated fluorescent microscope optimized for live-cell imaging, with mCherry expression showing cell growth rates and Sytox Green signal showing

cell death rates. Based on the results, determine the cell density that shows ~30% peak cell death rate within 24 hours after initial seeding.

For all subsequent experiments, seed cells at that chosen density in growth medium containing 0.75% methylcellulose. The methylcellulose will prevent excessive aggregation of cells in spheroid culture and maintain even spheroid size. Spheroids should be split every 3-4 days. To passage cells, dilute cells in PBS (~3x medium volume) to reduce the medium's viscosity. Collect spheroid pellets via centrifugation. To collect single cells, add Accutase to the pellets to dissociate the spheroids into single cells. Single cells can then be reseeded at the chosen density. See Appendix 10.3 for detailed protocol.

5.2.b. *Hess Lab Cell Line Maintenance*

Thawing Protocol: This protocol is developed by Hess Lab [77]. New media is prepared in a 15 mL tube. Slowly mix the media in the cryovial to thaw cell pellets. Once thawed, cells are pelleted by centrifugation and resuspended in fresh media. Cells need to be grown for typically 3 days before passaging further. See Appendix 10.2 for detailed protocol.

Passaging Protocol: This protocol is developed by Hess Lab [77]. This assumes passaging in a T75 flask (is using a T150, double the volume). Media is removed via aspiration. Wash cells with PBS then detach cells from the culture vessel with trypsin, then media is re-added to inactivate the trypsin. Cells are moved to a 15 mL conical tube, pelleted by centrifugation, and resuspended in new media. Add cell suspension to a new flask and add new media, enough to cover the cells. See Appendix 10.2 for detailed protocol.

5.2.c. *Lentiviral infection protocol*

This protocol was developed by Hess Lab [78]. First, one should count and plate the number of cells listed above for each infection in a well of a 24-well plate (see Appendix 10.4). After filtering with a 0.45nM filter, 1-2 mL of virus(es) are added to each well and left to incubate for 24 hours at 37°C. After incubating, viral media is aspirated from each well and replaced with 1 mL of proper media. 48-72 hours later, the cells should be ready for analysis by fluorescence or selection with antibiotics. See Appendix 10.4 for detailed protocol.

5.2.d. *High-throughput CRISPR screen protocol*

High-throughput, pooled CRISPR-Cas9 loss-of-function screening protocol is based on Mathiowetz *et al*, 2023 [79] and may be modified to better suit this project's needs. Constitutive Cas9-expressing cells are first generated through lentiviral transduction. A dose response analysis is then performed to determine the concentration of cytotoxic compounds. For antibiotic selection, this analysis can either be a drug-resistance screen or a drug-sensitivity screen. Next, the dynamic range of the reporter for fluorescence-based assays is determined (aim for a greater distance between high and low fluorescence intensity bins). The sgRNA library is prepared, either by amplification and packaging into lentivirus or purchased as pre-packaged in lentivirus. The sgRNA is introduced via lentiviral transduction (note: this step can be done either together

or separately from the Cas-9 introduction step). sgRNAs present in each cell population are then identified by extracting genomic DNA (gDNA) from frozen cell pellets and amplified by polymerase chain reaction (PCR). The pooled sgRNA library is sent for deep sequencing and readings are analyzed using casTLE. See Appendix 10.5 for detailed protocol.

5.3. *Testing*

5.3.a. *qPCR for Stemness Markers*

This protocol was developed by Hess Lab [80]. A quantitative polymerase chain reaction (qPCR) will be performed to test for the expression level of stemness marker genes indicative of spheroid formation. For the purposes of this project, SOX2 and KLF4 will be the marker genes selected due to their association and upregulation in A549 spheroid cells [81].

First, RNA is extracted using QuickExtract RNA Extraction Kit. cDNA template is then synthesized using extracted RNA. Primers for gene(s) of interest are designed, along with preparing a loading control primer (Hess Lab has designed primers for GAPDH and RPL19). qPCR is then performed using the SYBR Green method. CT values obtained for experimental samples compared to control are analyzed to determine if the expression of gene(s) of interest has been perturbed. See Appendix 10.6 for detailed protocol.

6. Results

There are no testing results available at this time. This section will recap the important numerical data resulting from the testing mentioned in section 5.3.

7. Discussion

Mimicking a 3D tumor environment using A549 cell line spheroids to be utilized for CRISPR interference (CRISPRi) screening can lead to identifying sources of DNA mutations that act as cancer drivers or have the potential to damage cancer cells. The successful implementation of this model could have significant theoretical implications. It may enable earlier detection of cancer and the development of new therapeutic tools and genomic therapies. These therapies could be more personalized, tailored to the genetic profile of individual patients, thereby improving treatment efficacy.

The A549 cell line was chosen due to its favorable properties for forming spheroids. These cells are known to form uniform spheroids efficiently, which is crucial for consistent experimental results. Additionally, the treated tissue culture plates used in this study are cost-effective and user-friendly, making them suitable for large-scale applications. The team anticipates that the A549 cells will successfully form spheroids, allowing for the production of a sufficient quantity for CRISPRi screening. This will help identify key genetic mutations involved in cancer progression and potential therapeutic targets.

There are several limitations and challenges associated with this study. Working with BSL-2 (Biosafety Level 2) requires specialized training and supervision, which can be a logistical hurdle. Additionally, cell behavior can be unpredictable, and there is a possibility that the cells may not form spheroids as expected, which could impact the testing outcomes.

Lastly, future work will involve testing the processes of dissociation, staining, and fixing the spheroid cells for gamma-H2AX. This will help determine if these processes affect any changes induced in the cells due to their association in spheroids and how these changes might influence the results of spheroid screening. Our goal is to refine these methods and achieve significant milestones by May 2025.

8.   Conclusions

The project aims to develop a 3D cell culture model compatible with CRISPR interference (CRISPRi) screening to better identify sources of DNA damage and mutations in cancer, overcoming the limitations of traditional 2D models. By using γH2AX staining to quantify DNA double-strand breaks and conducting high-throughput CRISPR screening, the team seeks to enhance the understanding of cancer progression and improve therapeutic strategies.

The team has selected the A549 adenocarcinoma non-small cell lung cancer cell line based on its favorable characteristics, including doubling time, adherence properties, and relevant genetic mutations. For spheroid formation, treated tissue culture plates have been chosen due to their cost-effectiveness and ability to produce consistent and predictable outcomes.

By bridging the gap between in vitro studies and clinical applications, the team aims to provide valuable insights that could lead to more effective cancer therapies and improved patient outcomes. Mimicking the 3D tumor environment allows for a more accurate study of the pathways involved in DNA damage response, offering new avenues for intervention in cancer treatment.

9. References

[1] "Cancer Facts & Figures 2022." Accessed: Oct. 09, 2024. [Online]. Available: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html

[2] M. Kapałczyńska *et al.*, "2D and 3D cell cultures – a comparison of different types of cancer cell cultures," *Arch. Med. Sci. AMS*, vol. 14, no. 4, pp. 910–919, Jun. 2018, doi: 10.5114/aoms.2016.63743.

[3] "2D vs 3D cell culture | Learning Center," 2D vs 3D cell culture | Learning Center | UPM Biomedicals. Accessed: Oct. 03, 2024. [Online]. Available: https://www.upmbiomedicals.com/resource-center/learning-center/what-is-3d-cell-culture/2d-versus-3d-cell-culture/

[4] "2D vs 3D cell culture | Learning Center | UPM Biomedicals." Accessed: Oct. 13, 2024. [Online]. Available: https://www.upmbiomedicals.com/resource-center/learning-center/what-is-3d-cell-culture/2d-versus-3d-cell-culture/

[5] admin.facellitate, "What are primary cells : advantages and limitations," faCellitate. Accessed: Oct. 14, 2024. [Online]. Available: https://facellitate.com/what-are-primary-cells-advantages-and-limitations/

[6] J.-P. Gillet, S. Varma, and M. M. Gottesman, "The Clinical Relevance of Cancer Cell Lines," *JNCI J. Natl. Cancer Inst.*, vol. 105, no. 7, pp. 452–458, Apr. 2013, doi: 10.1093/jnci/djt007.

[7] C. He *et al.*, "CRISPR screen in cancer: status quo and future perspectives," *Am. J. Cancer Res.*, vol. 11, no. 4, pp. 1031–1050, Apr. 2021.

[8] S. Dasari and P. B. Tchounwou, "Cisplatin in cancer therapy: molecular mechanisms of action," *Eur. J. Pharmacol.*, vol. 740, pp. 364–378, Oct. 2014, doi: 10.1016/j.ejphar.2014.07.025.

[9] B. Devanabanda and A. Kasi, "Oxaliplatin," in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Oct. 14, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK557690/

[10] "Bleomycin - StatPearls - NCBI Bookshelf." Accessed: Oct. 14, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK555895/

[11] L. Morrison, J. A. Laukkanen, K. Ronkainen, S. Kurl, J. Kauhanen, and A. T. Toriola, "Inflammatory biomarker score and cancer: A population-based prospective cohort study," *BMC Cancer*, vol. 16, p. 80, Feb. 2016, doi: 10.1186/s12885-016-2115-6.

[12] J. Fan *et al.*, "Multiplex gene quantification as digital markers for extremely rapid evaluation of chemo-drug sensitivity," *Patterns*, vol. 2, no. 10, p. 100360, Sep. 2021, doi: 10.1016/j.patter.2021.100360.

[13] N. Takahashi *et al.*, "3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis," *Mol. Cell*, vol. 80, no. 5, pp. 828-844.e6, Dec. 2020, doi: 10.1016/j.molcel.2020.10.010.

[14] K. Han *et al.*, "CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities," *Nature*, vol. 580, no. 7801, pp. 136–141, Apr. 2020, doi: 10.1038/s41586-020-2099-x.

[15] J. R. Ferrarone *et al.*, "Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase," *Proc. Natl. Acad. Sci.*, vol. 121, no. 21, p. e2403685121, May 2024, doi: 10.1073/pnas.2403685121.

[16] T. Stiff, S. Bayraktar, P. Dama, J. Stebbing, and L. Castellano, "CRISPR screens in 3D tumourspheres identified miR-4787-3p as a transcriptional start site miRNA essential for breast tumour-initiating cell growth," *Commun. Biol.*, vol. 7, no. 1, pp. 1–11, Jul. 2024, doi: 10.1038/s42003-024-06555-1.

[17] S. Gopal, A. L. Rodrigues, and J. S. Dordick, "Exploiting CRISPR Cas9 in Three-Dimensional Stem Cell Cultures to Model Disease," *Front. Bioeng. Biotechnol.*, vol. 8, Jun. 2020, doi: 10.3389/fbioe.2020.00692.

[18] "Hess, Gaelen," Integrated Program in Biochemistry. Accessed: Oct. 05, 2024. [Online]. Available: https://ipib.wisc.edu/staff/hess-gaelen/

[19] R. Blanco *et al.*, "A Gene-Alteration Profile of Human Lung Cancer Cell Lines," *Hum. Mutat.*, vol. 30, no. 8, pp. 1199–1206, Aug. 2009, doi: 10.1002/humu.21028.

[20] CDC, "Biosafety in Microbiological and Biomedical Laboratories—6th Edition," p. 37, Jun. 2020.

[21] "Freezing Cells - US." Accessed: Oct. 13, 2024. [Online]. Available: https://www.thermofisher.com/us/en/home/references/gibco-cell-culture-basics/cell-culture-protocols/freezing-cells.html

[22] M. Selby *et al.*, "3D Models of the NCI60 Cell Lines for Screening Oncology Compounds," *SLAS Discov. Adv. Life Sci. R D*, vol. 22, no. 5, pp. 473–483, Jun. 2017, doi: 10.1177/2472555217697434.

[23] "NCI-H23 [H23] - CRL-5800 | ATCC." Accessed: Sep. 25, 2024. [Online]. Available: https://www.atcc.org/products/crl-5800

[24] N. Takahashi *et al.*, "3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis," *Mol. Cell*, vol. 80, no. 5, pp. 828-844.e6, Dec. 2020, doi: 10.1016/j.molcel.2020.10.010.

[25] "Cell Line:905942 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer." Accessed: Sep. 27, 2024. [Online]. Available: https://www.cancerrxgene.org/cellline/NCI-H23/905942

[26] "A549 - CCL-185 | ATCC." Accessed: Sep. 25, 2024. [Online]. Available: https://www.atcc.org/products/ccl-185

[27] L. Korrodi-Gregório, V. Soto-Cerrato, R. Vitorino, M. Fardilha, and R. Pérez-Tomás, "From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research," *PLoS ONE*, vol. 11, no. 11, p. e0165973, Nov. 2016, doi: 10.1371/journal.pone.0165973.

[28] "OVCAR-5 Human Cancer Cell Line | SCC259." Accessed: Sep. 27, 2024. [Online]. Available: https://www.emdmillipore.com/US/en/product/OVCAR-5-Human-Cancer-Cell-Line,MM_NF-SCC259?ReferrerURL=https%3A%2F%2Fwww.google.com%2F

[29] B. C. Baguley *et al.*, "Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer," *Eur. J. Cancer Oxf. Engl. 1990*, vol. 31A, no. 2, pp. 230–237, 1995, doi: 10.1016/0959-8049(94)00472-h.

[30] "Cell Line:905969 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer." Accessed: Sep. 27, 2024. [Online]. Available: https://www.cancerrxgene.org/cellline/OVCAR-5/905969

[31] "OVCAR-5/RFP cell line." Accessed: Sep. 30, 2024. [Online]. Available: https://www.mybiosource.com/cell-line/ovcar-5-rfp/168983

[32] W. Asghar *et al.*, "In Vitro Three-Dimensional Cancer Culture Models," *Cancer Target. Drug Deliv. Elus. Dream*, pp. 635–665, Jul. 2013, doi: 10.1007/978-1-4614-7876-8-24.

[33] L. Carroll, B. Tiwari, J. Curtin, and J. Wanigasekara, "U-251MG Spheroid Generation Using Hanging Drop Method Protocol," May 2021, Accessed: Sep. 27, 2024. [Online]. Available: https://www.protocols.io/view/u-251mg-spheroid-generation-using-hanging-drop-met-btstnnen

[34] "Generation and Cultivation of 3D Cell Models," ibidi. Accessed: Oct. 10, 2024. [Online]. Available: https://ibidi.com/content/1037-generation-and-cultivation-of-3d-cell-models

[35] A. P. P. Guimaraes, I. R. Calori, H. Bi, and A. C. Tedesco, "SpheroMold: modernizing the hanging drop method for spheroid culture," *Front. Drug Deliv.*, vol. 4, Jun. 2024, doi: 10.3389/fddev.2024.1397153.

[36] "Perfecta3D Hanging Drop Plates - 96-Well." Accessed: Oct. 10, 2024. [Online]. Available: https://www.selectscience.net/product/perfecta3d-hanging-drop-plates-96-well

[37] S. S. Nazari, "Generation of 3D Tumor Spheroids with Encapsulating Basement Membranes for Invasion Studies," *Curr. Protoc. Cell Biol.*, vol. 87, no. 1, p. e105, 2020, doi: 10.1002/cpcb.105.

[38] M. A. Badea *et al.*, "Influence of Matrigel on Single- and Multiple-Spheroid Cultures in Breast Cancer Research," *SLAS Discov.*, vol. 24, no. 5, pp. 563–578, Jun. 2019, doi: 10.1177/2472555219834698.

[39] "Overview of Cell Viability and Survival," Cell Signaling Technology. Accessed: Sep. 27, 2024.

[Online]. Available: https://www.cellsignal.com/science-resources/cell-viability-and-survival

[40] M. M. Silva, C. R. R. Rocha, G. S. Kinker, A. L. Pelegrini, and C. F. M. Menck, "The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells," *Sci. Rep.*, vol. 9, p. 17639, Nov. 2019, doi: 10.1038/s41598-019-54065-6.

[41] A. R. Hyler *et al.*, "Fluid shear stress impacts ovarian cancer cell viability, subcellular organization, and promotes genomic instability," *PLoS ONE*, vol. 13, no. 3, p. e0194170, Mar. 2018, doi: 10.1371/journal.pone.0194170.

[42] R. Zhang, X. Chen, S. Fu, L. Xu, and J. Lin, "A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells," *Oncol. Rep.*, vol. 44, no. 3, pp. 1224–1232, Sep. 2020, doi: 10.3892/or.2020.7667.

[43] J. N. Søndergaard, K. Geng, C. Sommerauer, I. Atanasoai, X. Yin, and C. Kutter, "Successful delivery of large-size CRISPR/Cas9 vectors in hard-to-transfect human cells using small plasmids," *Commun. Biol.*, vol. 3, p. 319, Jun. 2020, doi: 10.1038/s42003-020-1045-7.

[44] T. Kim, I. Doh, and Y.-H. Cho, "On-chip three-dimensional tumor spheroid formation and pump-less perfusion culture using gravity-driven cell aggregation and balanced droplet dispensing," *Biomicrofluidics*, vol. 6, no. 3, p. 034107, Jul. 2012, doi: 10.1063/1.4739460.

[45] C. D. House, L. Hernandez, and C. M. Annunziata, "In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells," *J. Vis. Exp. JoVE*, no. 96, p. 52446, Feb. 2015, doi: 10.3791/52446.

[46] "OVCAR-5 Cell Avalanche® Transfection Reagent – EZ Biosystems." Accessed: Sep. 25, 2024. [Online]. Available: https://ezbiosystems.com/product/ovcar-5-cell-avalanche-transfection-reagent/

[47] J.-C. Cheng, C. Klausen, and P. C. K. Leung, "Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells," *Cancer Lett.*, vol. 329, no. 2, pp. 197–206, Feb. 2013, doi: 10.1016/j.canlet.2012.10.029.

[48] "Cell Doubling Time Calculator." Accessed: Sep. 25, 2024. [Online]. Available: https://www.omnicalculator.com/biology/cell-doubling-time

[49] "Cellosaurus - Cell line encyclopedia." Accessed: Sep. 25, 2024. [Online]. Available: https://www.cellosaurus.org/index.html

[50] "Home page - Cancerrxgene - Genomics of Drug Sensitivity in Cancer." Accessed: Sep. 27, 2024. [Online]. Available: https://www.cancerrxgene.org/

[51] "Cell Line:905949 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer." Accessed: Sep. 27, 2024. [Online]. Available: https://www.cancerrxgene.org/cellline/A549/905949

[52] "TP53 tumor protein p53 BCC7 LFS1 P53 TRP53 | Sigma-Aldrich." Accessed: Sep. 19, 2024. [Online]. Available: https://www.sigmaaldrich.com/US/en/genes/tp53

[53] "EGFR epidermal growth factor receptor ERBB ERBB1 HER1 PIG61 mENA | Sigma-Aldrich." Accessed: Sep. 20, 2024. [Online]. Available: https://www.sigmaaldrich.com/US/en/genes/egfr

[54] "KRAS Kirsten rat sarcoma viral oncogene homolog C-K-RAS CFC2 K-RAS2A K-RAS2B K-RAS4A K-RAS4B KI-RAS KRAS1 KRAS2 NS NS3 RASK2 | Sigma-Aldrich." Accessed: Sep. 19, 2024. [Online]. Available: https://www.sigmaaldrich.com/US/en/genes/kras

[55] R. Mirgayazova *et al.*, "Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?," *Genes*, vol. 11, no. 6, p. 704, Jun. 2020, doi: 10.3390/genes11060704.

[56] "PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha CLOVE CWS5 MCAP MCM MCMTC PI3K p110-alpha | Sigma-Aldrich." Accessed: Sep. 27, 2024. [Online]. Available: https://www.sigmaaldrich.com/US/en/genes/pik3ca

[57] S.-Q. Hou, M. Ouyang, A. Brandmaier, H. Hao, and W. H. Shen, "PTEN in the maintenance of genome integrity: From DNA replication to chromosome segregation," *BioEssays News Rev. Mol. Cell. Dev. Biol.*, vol. 39, no. 10, p. 10.1002/bies.201700082, Oct. 2017, doi: 10.1002/bies.201700082.

[58] E. Ó hAinmhire, S. M. Quartuccio, W. Cheng, R. A. Ahmed, S. M. King, and J. E. Burdette, "Mutation or Loss of p53 Differentially Modifies TGFβ Action in Ovarian Cancer," *PLoS ONE*, vol. 9, no. 2, p. e89553, Feb. 2014, doi: 10.1371/journal.pone.0089553.

[59] "CLDN4 claudin 4 [Homo sapiens (human)] - Gene - NCBI." Accessed: Sep. 27, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/gene/1364

[60] T. Riss and O. J. Trask, "Factors to consider when interrogating 3D culture models with plate readers or automated microscopes," *In Vitro Cell. Dev. Biol. Anim.*, vol. 57, no. 2, pp. 238–256, 2021, doi: 10.1007/s11626-020-00537-3.

[61] H. Shi *et al.*, "3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies," *Front. Oncol.*, vol. 12, p. 973576, Aug. 2022, doi: 10.3389/fonc.2022.973576.

[62] Y.-C. Chen, X. Lou, Z. Zhang, P. Ingram, and E. Yoon, "High-Throughput Cancer Cell Sphere Formation for Characterizing the Efficacy of Photo Dynamic Therapy in 3D Cell Cultures," *Sci. Rep.*, vol. 5, no. 1, p. 12175, Jul. 2015, doi: 10.1038/srep12175.

[63] A. P. Aijian and R. L. Garrell, "Digital Microfluidics for Automated Hanging Drop Cell Spheroid Culture," *SLAS Technol.*, vol. 20, no. 3, pp. 283–295, Jun. 2015, doi: 10.1177/2211068214562002.

[64] R. Teixeira Polez, N. Huynh, C. S. Pridgeon, J. J. Valle-Delgado, R. Harjumäki, and M. Österberg, "Insights into spheroids formation in cellulose nanofibrils and Matrigel hydrogels using AFM-based techniques," *Mater. Today Bio*, vol. 26, p. 101065, Jun. 2024, doi: 10.1016/j.mtbio.2024.101065.

[65] N.-E. Ryu, S.-H. Lee, and H. Park, "Spheroid Culture System Methods and Applications for Mesenchymal Stem Cells," *Cells*, vol. 8, no. 12, p. 1620, Dec. 2019, doi: 10.3390/cells8121620.

[66] "Low Attachment Cell Culture Plates, Dishes, and Flasks - US." Accessed: Sep. 27, 2024. [Online]. Available: https://www.thermofisher.com/us/en/home/life-science/cell-culture/organoids-spheroids-3d-cell-culture/3d-cell-culture-plates-dishes-flasks.html

[67] "Trypsin-EDTA (0.05%), phenol red." Accessed: Sep. 27, 2024. [Online]. Available: https://www.thermofisher.com/order/catalog/product/25300054

[68] "RNase A, DNase and protease-free (10 mg/mL)." Accessed: Sep. 27, 2024. [Online]. Available: https://www.thermofisher.com/order/catalog/product/EN0531

[69] R. Foty, "A Simple Hanging Drop Cell Culture Protocol for Generation of 3D Spheroids," *J. Vis. Exp. JoVE*, no. 51, p. 2720, May 2011, doi: 10.3791/2720.

[70] "Corning® Matrigel® Basement Membrane Matrix -." Accessed: Sep. 27, 2024. [Online]. Available: https://www.sigmaaldrich.com/US/en/substance/corningmatrigelbasementmembranematrix1234598765

[71] "A549 Cell Line Maintenance · Benchling." Accessed: Oct. 05, 2024. [Online]. Available: https://benchling.com/uw_hesslab/f/lib_tD5E8G7L-cell-line-maintenance/etr_5Skd74TL-a549-cell-line-maintenance/edit

[72] "T75 Flasks - US." Accessed: Oct. 13, 2024. [Online]. Available: https://www.thermofisher.com/us/en/home/life-science/cell-culture/cell-culture-plastics/cell-culture-flasks/t75-flasks.html

[73] "DMEM, high glucose, no glutamine." Accessed: Oct. 13, 2024. [Online]. Available: https://www.thermofisher.com/order/catalog/product/11960044

[74] "Penicillin-Streptomycin (5,000 U/mL)." Accessed: Oct. 13, 2024. [Online]. Available: https://www.thermofisher.com/order/catalog/product/15070063

[75] "Fetal Bovine Serum, Value (formerly USDA-approved in North America or qualified, Brazil in other regions)." Accessed: Oct. 13, 2024. [Online]. Available: https://www.thermofisher.com/order/catalog/product/A5256701

[76] "PBS, pH 7.4." Accessed: Oct. 13, 2024. [Online]. Available: https://www.thermofisher.com/order/catalog/product/10010023

[77] "Passaging Cells · Benchling." Accessed: Oct. 05, 2024. [Online]. Available: https://benchling.com/uw_hesslab/f/lib_jUyOwxBE-tissue-culture-protocols/prt_PWYXyJOG-passaging-cells/edit

[78] "Small scale infection of mammalian cells with Lentivirus: Adherent Cells Version · Benchling."

Accessed: Oct. 05, 2024. [Online]. Available:
https://benchling.com/uw_hesslab/f/lib_jUyOwxBE-tissue-culture-protocols/prt_Sdt7mJ5N-small-s
cale-infection-of-mammalian-cells-with-lentivirus-adherent-cells-version/edit

[79] A. J. Mathiowetz, M. A. Roberts, D. W. Morgens, J. A. Olzmann, and Z. Li, "Protocol for performing pooled CRISPR-Cas9 loss-of-function screens," *STAR Protoc.*, vol. 4, no. 2, p. 102201, Mar. 2023, doi: 10.1016/j.xpro.2023.102201.

[80] "qPCR Protocol · Benchling." Accessed: Oct. 10, 2024. [Online]. Available:
https://benchling.com/uw_hesslab/f/lib_xtPaCTIU-extraction-and-staining-protocols/prt_Va3aG4Cc
-qpcr-protocol/edit

[81] C. Choe, H. Kim, S. Min, S. Park, J. Seo, and S. Roh, "SOX2, a stemness gene, induces progression of NSCLC A549 cells toward anchorage-independent growth and chemoresistance to vinblastine," *OncoTargets Ther.*, vol. 11, pp. 6197–6207, Sep. 2018, doi: 10.2147/OTT.S175810.

10.   Appendix

10.1.   Product Design Specifications

Created: September 19, 2024

Function: Although previous CRISPRi screening in 2D monolayers has provided useful knowledge on cancer drivers and therapeutic susceptibilities, it lacks an element of biological relevance to an *in vivo* environment. Therefore, our team was tasked with developing a cell culture method that is compatible with a 3D environment and CRISPRi screening in order to identify sources of DNA mutations in the tumor environment. On a high scale, the team must select a viable cell line for the screen, create and optimize a spheroid formation protocol, and develop a protocol to stain for γH2AX: a histone variant that acts as a sensitive marker for DNA damage.

Client requirements:
1. The team must choose an appropriate human cell line for the project, ensuring to maximize cell spheroid viability.
2. The team must develop a spheroid formation protocol for the chosen cell type or line that optimizes seeding density and viscosity.
3. The team must optimize the cancer spheroid characteristics and their formation protocols for CRISPR screens.
4. By May 2025, the team must develop a protocol to stain for γH2AX: an indicator for the location of maximal damage due to DNA double-strand breaks (DSBs).
5. By May 2025, the team must perform high throughput genome-wide CRISPR screening to check for the effects of different genes on the amount of γH2AX detected.
6. Future steps post-design project include performing an analysis to determine the phenotypic differences between cells grown in monolayers (2D) versus cells grown as spheroids (3D).

Design requirements:
1. Physical and Operational Characteristics
   a. *Performance requirements:*
      i. Spheroid formation protocol should be scalable, repeatable, and optimized regarding:
         1. Seeding densities to ensure only 1 single guide (sgRNA) will enter each cell.
         2. Viscosity of growth medium (by changing the amount of methylcellulose) to ensure homogenous spheroid size.
         3. Optimizing reagent percentages of growth medium to ensure maximum cell growth.
      ii. γH2AX staining protocol should be scalable, repeatable and optimized regarding the antibody used and amount of reagents used.

b. *Safety:*
  i. Biosafety Level 2 (BSL-2) is necessary for work with agents associated with human tissue and disease including the human lung cancer cell line which the team will be using [1]. The following universal precautions for BSL-2 are used to reduce the risk of bloodborne pathogens:
    1. Laboratory personnel receive specific training in handling pathogenic agents and are supervised by scientists competent in handling infectious agents and associated procedures [1].
    2. Access to the laboratory is restricted when work is being conducted [1].
    3. All procedures in which infectious aerosols or splashes may be created are conducted in BSCs or other physical containment equipment [1].
  ii. Cultures, tissues, specimens of body fluids, or potentially infectious wastes are to be placed in a container with a cover that prevents leakage during handling, processing, and storage [2].
  iii. Although the team does not anticipate the need to remove our cells or cancer spheroids from Hess Lab, the following BSL-2 guideline must be followed.
    1. Biological agents prepared for transport must be placed in a secondary leak-proof, unbreakable carrier. Carriers must have the biohazard label, including the identity of the agent, affixed to the outer surface of the transport container [2].
  iv. If genome editing leads to the inactivation of tumor suppressors or activation of oncogenes in human cells, then oncogenesis becomes a possibility in the event of exposure [3]. This is a concern when:
    1. Genome editing components are delivered by a method that can enter human cells (e.g., viral vectors that can infect human cells).
    2. All components required for genome editing are likely to be introduced in a single exposure event, such as a needle stick or mucosal splash.
    3. Genome editing is designed to target human oncogenes/tumor suppressors or can target human oncogenes/tumor suppressors due to homology.
  v. A risk assessment and containment preparations for research with lentiviral vectors should consider (1) the nature of the vector system, (2) transgene insert, and (3) type of manipulations involved [4]. Either BL-2 or enhanced BL-2 will be appropriate for these such experiments. The major risks to be considered for research with HIV-1 based lentivirus

vectors are (1) potential for generation of replication-competent lentivirus (RCL) and (2) potential for oncogenesis [4]. These risks can be mitigated by the nature of the vector system (and its safety features) or exacerbated by the nature of the transgene insert encoded by the vector [4].

c. *Accuracy and Reliability:*
    i.   A starting cell seeding density of 50,000 cells/cm² will be used. Cells at these densities will be monitored for growth and death rates on a live-cell microscope for 60 hours to confirm a ~30% cell death rate during the initial growth phase of the spheroids [5].
    ii.   Cell seeding densities must be such that only 1 single guide (sgRNA) enters each cell to allow for analyzable results. Therefore, a total of 100-150 million cells will be required for each genome-wide CRISPR screen [6].
    iii.   A minimum of 3 γ-H2AX staining experiments will be performed to establish confidence in results.

d. *Life in Service:*
    i.   Before preparing them for CRISPRi screening, cells will need to be in culture for approximately 2 months to allow for optimization of the spheroid formation protocol, including the spheroids' size and cell quantity. This time period may consist of thawing a new vial of cells for continuing cell culture if the passage number exceeds 25 [7].
    ii.   After infection with the selected genome-wide library, a minimum of 6 days will be required before the cells can be further utilized [5].
    iii.   After generating spheroids from these cells, a minimum of 21 days will be required for the genome-wide screening [5].

e. *Shelf Life:*
    i.   When not in culture or experimental use, cells will be stored using cryogenics for long-term use. Frozen cells will be kept in cryovials with medium containing a cryoprotective agent like DMSO. These vials will be immersed in liquid nitrogen at a temperature below -135℃ [8].

f. *Operating Environment:*
    i.   Cells needed to generate spheroids for this project will be kept in standard incubation conditions: 37℃, 5% CO_2, and 90–95% relative humidity [9].
    ii.   Cells in culture will be maintained in a cell culture medium supplemented with fetal calf/bovine serum to deliver essential growth factors. The

medium will contain phenol red, which will indicate the need to replace it if it turns yellow (acidic) or purple (alkaline) [9].
    iii.   For preparation for CRISPRi screening, spheroid cells will be exposed to a pooled single-guide RNA (sgRNA) library and CRISPR associated protein 9 (Cas9) via lentiviral vectors [10].

g. *Ergonomics:*
    i.   Protocols should create a more efficient and accurate experimental system that better mimics *in vivo* tumor conditions, while proving the effects of γH2AX in DNA damage.
    ii.   The design of cell culture methods should be optimized by selecting appropriate cell lines and developing correct spheroid formations to enhance the accuracy, relevance, and scalability of CRISPRi screening in a 3D tumor model.
    iii.   The γH2AX staining protocol should be optimized for improved precision. Additionally, γH2AX foci counting should be performed via high-throughput screening for efficiency.

h. *Size:*
    i.   Spheroids will be generated in 60 mm tissue culture plates [5].
    ii.   Cell seeding density for spheroids will be restricted to 50,000 cells/cm² to ensure appropriate CRISPRi screening [5].
    iii.   To adhere to a spheroid size suitable for γH2AX staining, spheroids will be kept to ~500 μm in diameter [11].

i. *Weight:*
    i.   Although solutions have been presented for single-cell analysis, literature does not cover this aspect for 3D models such as spheroids [12]. Tools like a flow-apparatus are needed for the accurate measurements of mass density, size and weight of such spheroids [12].

j. *Materials:*
    i.   In order to leave room for the engineering design element, the client did not give specific requirements for materials other than cell type to be used for the project.
    ii.   The client has recommended that the team select a human lung cancer cell line that (1) adheres well to spheroids and (2) has a high percentage of viable cells.

k. *Appearance:*

        i.   Since the spheroids should have an overall appearance that will accurately replicate the 3D tumor microenvironment, the spheroids must be: translucent, porous, uniformly spherical, and have a stiffness analogous to the lung cancer cell line selected [13].

2. Production Characteristics
   a. *Quantity:*
      i. By the end of this semester, the team will design, fabricate, and develop two appropriate protocols for the chosen cell line, one for spheroid formation and one for γH2AX.
      ii. The final protocols should be capable of accurately mimicking the 3D tumor environment for CRISPR screening, including features for effective spheroid formation and reliable γH2AX staining to assess DNA changes.
      iii. The protocols can be adapted to other similar human cancer cell lines; however, some of the characteristics may be subjected to change.

   b. *Target Product Cost:*
      i. The budget for the project is $1,000. Some of the materials and services that the team expects to use are listed below; however, many are already available in Hess Lab and will not need to be purchased.
         1. Biological materials such as reagents (for various media), antibodies (for γH2AX staining) and lentivirus for gene insertion.
         2. Obtaining new cell lines if needed.
         3. Designing of CRISPR library.
      ii. This project is a part of an emerging field, so similar products on the market are not available for non-clinical purchasing purposes. Therefore, the target cost of the final prototype is to remain within the budget proposed.

3. Miscellaneous
   a. *Standards and Specifications:*
      i. Cell lines used for this project should comply with the requirements outlined in part 1b - *Safety* above. Specifically, cell lines used and their associated reagents and protocols will need to comply with requirements for BSL-2 labs; meaning, they are or will contain bacteria, viruses, and organisms that pose a moderate safety hazard to healthy adult humans [14].
      ii. The use of human cell lines and other organisms in research for this project is outlined in various standards and regulations including Section 29 CFR 1910.1030 *(OSHA Bloodborne Pathogens),* Section 21 CFR

876.5885 *(Tissue culture media for human ex vivo tissue and cell culture processing applications),* and a comprehensive cell line guideline by Geraughty, *et al* (2014):

1. Bloodborne pathogens are microorganisms in the blood that can infect and cause diseases in humans [15].
2. Human cell lines are designated by the FDA as Class II (Special Controls) [16].
3. If applicable, genetic modification processes on the cell line must be detailedly-noted and kept track of, including but not limited to, sequence details, insertion vectors and modes, and antibiotic resistance markers [17]. Following modification using lentivirus, cell lines may be additionally tested to confirm non-infectivity [17].

iii. Human cell lines that may be needed for this project are already available in the client's lab, or can be obtained from another lab, meaning they already comply with the requirements listed above. In the case that biological research materials are obtained from another lab or institute, an MTA (material-transfer agreements) must be signed by both the provider and recipient to define their rights regarding the materials [17].

iv. In the unlikely case that new human cell lines must be acquired, additional ethical and authentication considerations must be taken into account:

1. Ethical considerations are outlined in Part 3c - *Patient-related concerns* below.
2. For cell line authentication, short tandem repeat (STR) is the recommended profiling method, outlined in ASN-0002 *(Authentication of Human Cell Lines: Standardization of STR Profiling)* provided by the American National Standards Institute (ANSI) and the American Type Culture Collection (ATCC). STR is a DNA-based sequence method that allows for detection of mutations and adventitious agents, as well as confirmation of the origin of the interested cell line [18].

b. *Patient-related concerns:*

i. As cell lines and other tissue materials needed for this project are either already available in the client's lab or in another lab, their ethical and other patient-related considerations have already been considered.

ii. In the unlikely case that a new cell line is obtained from patients or donors, the Patient Consent Form and associated Patient Information Sheet will be needed to explain the need for the specimen and the purpose and importance of the research [17]. Patient/donor and original tissue

information such as age, sex, clinical history, site of origin, nature of tissue specimen, stage and grade of cancer or other disease/ pathology, and other important information must also be recorded.

iii. For maximal biological relevance to patient *in vivo* tissue, the team will ensure our spheroids are designed based on critical 3D parameters: stiffness analogous to lung cancer tissue, replication of the complex cell-cell interactions and cell-extracellular matrix (ECM) interactions, and increased accuracy in CRISPRi screening environment to better detect precancerous cells [19], [20].

c. *Competition:*

i. 3D cancer spheroid models that can be utilized for CRISPR-Cas9 screens have been implemented in previous research, with and without using an exogenous extracellular matrix (ECM).

1. Takahashi *et al*, 2020 utilized 4% Matrigel™ as a bio-scaffolding to plate A549 and H1437 cells spheroids, which can better model *in-vivo* interactions between cells and the ECM [21]. The study's CRISPRi library gene list as well as its phenotypes have a strong overlap with those from Han *et al*, 2020 (described below), suggesting that inner cells of ECM-based 3D spheroids may be similar to ECM-free 3D spheroids.

2. Han *et al*, 2020 devised an ECM-free scalable method to propagate 3D spheroids [5]. H23 cells were seeded on pre-treated ultra-low attachment or polyhema-covered plates in RPMI 1640 medium with 0.75% methylcellulose. Similar methods have been found to be implemented in other studies, such as by Ferrarone, *et al* (2024) and by Stiff, *et al* (2024) [22], [23]. A total of around 210,000 single guide RNAs (sgRNAs) were designed for the CRISPRi library with around 10 sgRNAs per gene [5]. Samples were used to calculate growth and/or tested for drug resistance [5].

3. 3D stem cell models have also been genomically edited via CRISPR-Cas9 to better model various disease phenotypes. Cells can be assembled with or without supporting scaffolds. Some example scaffolds include laminin-rich Matrigel, collagen matrix, or those that are naturally derived from decellularized tissues [24].

ii. γH2AX has been used in various research as a marker to monitor DNA damage and repair, such as in understanding the toxicity of cigarette smoke or in understanding the effects of chemotherapeutic treatments in cancer patients [25], [26]. High throughput systems have also been developed to aid with counting γH2AX foci [26].

References

[1] CDC, "Biosafety in Microbiological and Biomedical Laboratories—6th Edition," p. 37, Jun. 2020.

[2] NIH, "Laboratory Biosafety Manual BSL-2 and BSL 2/3." Accessed: Sep. 12, 2024. [Online]. Available: https://ors.od.nih.gov/sr/dohs/Documents/bsl-2-lab-safety-manual.pdf

[3] University of Wisconsin-Madison Office of Biological Safety, "Biosafety Guide to CRISPR." Accessed: Sep. 12, 2024. [Online]. Available: https://ehs.wisc.edu/wp-content/uploads/sites/1408/2022/04/EHS-BIO-GUI-034-V02.pdf

[4] NIH, "Lenti_Containment_Guidance.pdf," Major RAC Concerns. Accessed: Sep. 15, 2024. [Online]. Available: https://osp.od.nih.gov/wp-content/uploads/Lenti_Containment_Guidance.pdf

[5] K. Han *et al.*, "CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities," *Nature*, vol. 580, no. 7801, pp. 136–141, Apr. 2020, doi: 10.1038/s41586-020-2099-x.

[6] V. Chenouard *et al.*, "Excess of guide RNA reduces knockin efficiency and drastically increases on-target large deletions," *iScience*, vol. 26, no. 4, p. 106399, Mar. 2023, doi: 10.1016/j.isci.2023.106399.

[7] C. Zheng, Y. Sun, X. Ye, H. Chen, and H. Ji, "Establishment and characterization of primary lung cancer cell lines from Chinese population," *Acta Pharmacol. Sin.*, vol. 32, no. 3, pp. 385–392, Mar. 2011, doi: 10.1038/aps.2010.214.

[8] "Freezing Cells - US." Accessed: Sep. 14, 2024. [Online]. Available: https://www.thermofisher.com/us/en/home/references/gibco-cell-culture-basics/cell-culture-protocols/freezing-cells.html

[9] "Cell Culture | Parameters for Healthy Cells," ibidi. Accessed: Sep. 14, 2024. [Online]. Available: https://ibidi.com/content/435-parameters-for-healthy-cells

[10] "Introduction to CRISPR screening | IDT," Integrated DNA Technologies. Accessed: Sep. 14, 2024. [Online]. Available: https://www.idtdna.com/pages/education/decoded/article/overview-what-is-crispr-screening

[11] M. Selby *et al.*, "3D Models of the NCI60 Cell Lines for Screening Oncology Compounds," *SLAS Discov.*, vol. 22, no. 5, pp. 473–483, Jun. 2017, doi: 10.1177/2472555217697434.

[12] D. A. Cristaldi *et al.*, "A Reliable Flow-Based Method for the Accurate Measure of Mass Density, Size and Weight of Live 3D Tumor Spheroids," *Micromachines*, vol. 11, no. 5, p. 465, Apr. 2020, doi: 10.3390/mi11050465.

[13] Thermo Fisher Scientific, "generation-cancer-spheroids-tips-tricks-application-note.pdf," Generation of cancer spheroids— tips and tricks. Accessed: Sep. 15, 2024. [Online]. Available: https://assets.thermofisher.com/TFS-Assets/BID/Application-Notes/generation-cancer-spheroids-tips-tricks-application-note.pdf

[14] "Biosafety Levels and Their Meaning - Eppendorf US." Accessed: Sep. 17, 2024. [Online]. Available: https://www.eppendorf.com/us-en/lab-academy/life-science/cell-biology/biosafety-levels-and-their-meaning/

[15] "1910.1030 - Bloodborne pathogens. | Occupational Safety and Health Administration." Accessed: Sep. 17, 2024. [Online]. Available:

https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030

[16]   "CFR - Code of Federal Regulations Title 21." Accessed: Sep. 17, 2024. [Online].
       Available:
       https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=876.5885

[17]   R. J. Geraghty *et al.*, "Guidelines for the use of cell lines in biomedical research," *Br. J.
       Cancer*, vol. 111, no. 6, pp. 1021–1046, Sep. 2014, doi: 10.1038/bjc.2014.166.

[18]   J. L. Almeida, K. D. Cole, and A. L. Plant, "Standards for Cell Line Authentication and
       Beyond," *PLoS Biol.*, vol. 14, no. 6, p. e1002476, Jun. 2016, doi:
       10.1371/journal.pbio.1002476.

[19]   W. M. Bonner *et al.*, "γH2AX and cancer," *Nat. Rev. Cancer*, vol. 8, no. 12, pp. 957–967,
       Dec. 2008, doi: 10.1038/nrc2523.

[20]   I. Padmalayam and M. J. Suto, "Chapter Twenty-Four - 3D Cell Cultures: Mimicking In
       Vivo Tissues for Improved Predictability in Drug Discovery," in *Annual Reports in
       Medicinal Chemistry*, vol. 47, M. C. Desai, Ed., in Annual Reports in Medicinal Chemistry,
       vol. 47. , Academic Press, 2012, pp. 367–378. doi: 10.1016/B978-0-12-396492-2.00024-2.

[21]   N. Takahashi *et al.*, "3D Culture Models with CRISPR Screens Reveal Hyperactive
       NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and
       Ferroptosis," *Mol. Cell*, vol. 80, no. 5, pp. 828-844.e6, Dec. 2020, doi:
       10.1016/j.molcel.2020.10.010.

[22]   J. R. Ferrarone *et al.*, "Genome-wide CRISPR screens in spheroid culture reveal that the
       tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase," *Proc. Natl. Acad.
       Sci.*, vol. 121, no. 21, p. e2403685121, May 2024, doi: 10.1073/pnas.2403685121.

[23]   T. Stiff, S. Bayraktar, P. Dama, J. Stebbing, and L. Castellano, "CRISPR screens in 3D
       tumourspheres identified miR-4787-3p as a transcriptional start site miRNA essential for
       breast tumour-initiating cell growth," *Commun. Biol.*, vol. 7, no. 1, pp. 1–11, Jul. 2024, doi:
       10.1038/s42003-024-06555-1.

[24]   S. Gopal, A. L. Rodrigues, and J. S. Dordick, "Exploiting CRISPR Cas9 in
       Three-Dimensional Stem Cell Cultures to Model Disease," *Front. Bioeng. Biotechnol.*, vol.
       8, Jun. 2020, doi: 10.3389/fbioe.2020.00692.

[25]   C. Garcia-Canton, A. Anadón, and C. Meredith, "γH2AX as a novel endpoint to detect
       DNA damage: Applications for the assessment of the *in vitro* genotoxicity of cigarette
       smoke," *Toxicol. In Vitro*, vol. 26, no. 7, pp. 1075–1086, Oct. 2012, doi:
       10.1016/j.tiv.2012.06.006.

[26]   A. Ivashkevich, C. E. Redon, A. J. Nakamura, R. F. Martin, and O. A. Martin, "USE OF
       THE γ-H2AX ASSAY TO MONITOR DNA DAMAGE AND REPAIR IN
       TRANSLATIONAL CANCER RESEARCH," *Cancer Lett.*, vol. 327, no. 1–2, pp. 123–133,
       Dec. 2012, doi: 10.1016/j.canlet.2011.12.025.

10.2.   *Hess Cell Line Maintenance Protocol*

Thawing

1) Prepare 10mL of the appropriate media in a 15ml tube.
2) Using a P1000 slowly mix the media in the cryovial to thaw the pellet of cells.
3) Set the pipette to something below 1000uL, maybe 900uL to avoid clogging the filter while resuspending
4) Once thawed, add to the remaining media and spin down at 1400 rpm for 5 min.
5) Resuspend the cells in fresh media and add to a flask to incubate for typically 3 days before passaging further.

Passaging Adherent (eg. A549) Cell Line

1) This assumes passaging in a T75 flask, if using a T150, double the volumes)
2) Remove all media with Pasteur pipette and vacuum
3) Add 2ml of PBS to remove remaining media and remove with vacuum
4) Add 2mL trypsin and wait five min at 37C
5) Add 6mL media to neutralize trypsin while mixing to remove cells from the bottom of the flask (at least 3x the volume of trypsin used)
6) Wash the flask with the cells in media, remove and add to a 15ml conical tube
7) Return enough media to the flask so cells will be confluent when next checked
8) Add additional media (eg. 10 ml)
9) The media just needs to be enough to cover the cells, provide nutrients and won't dry out. Adding more media doesn't change the confluence of the cells.

Counting Cells

10) Add 100uL of cells in media to 900ul PBS in a microcentrifuge tube.
11) This may not be necessary for less confluent cells, but highly dense cells, especially adherent cells, tend to clump together and throw off the count.
12) Measure 10uL on the cytometer and gate for the live population of cells
13) Use the "live" number of events to calculate the confluence and total number of cells you have.
14) Since the cells have been diluted 1:10, the "live" events gives you the number of cells per uL, multiply this by 1000 to get the number of cells per mL.

References

[1] "Passaging Cells · Benchling." Accessed: Oct. 05, 2024. [Online]. Available: https://benchling.com/uw_hesslab/f/lib_jUyOwxBE-tissue-culture-protocols/prt_PWYXyJOG-passaging-cells/edit

10.3. *Spheroid formation protocol*

Materials:
- Poly-HEMA (Sigma, no. P3932)
- Chosen cell line
- Full cell culture growth medium for chosen cell line
- Methylcellulose (0.75%; Fisher, no. M-352)
- Accutase (Innovative Cell Technologies, no. AT104)

Procedure:
1) Seed cells at multiple densities ranging from 200,000-150,000 cells/cm² (with 500 μL growth medium/cm²).
2) Monitor cell growth and death rates using an automated fluorescent microscope optimized for live-cell imaging (i.e. IncuCyte S3 or IncuCyte ZOOM, Essen Bioscience).
   a) Monitor cell growth rates by mCherry expressed in the cell line.
      i) Estimate the number of live cells in spheroids by dividing total integrated mCherry intensities of spheroids by the average integrated mCherry intensity of single live cells measured during initial seeding.
   b) Monitor death rates by Sytox Green signal. Sytox Green should be added at 100 nM final concentration at the beginning of the experiment.
      i) Estimate the number of dead cells by dividing the total integrated Sytox Green intensities of spheroids by the average integrated Sytox Green intensity of a single dead cell.
3) From the above results, choose a cell density which shows ~30% peak cell death rate within 24 hours after initial seeding. For all subsequent experiments, initially seed cells with this cell density in 500 μL medium containing 0.75% methylcellulose. The methylcellulose will prevent excessive aggregation of cells in spheroid culture and maintain even spheroid size.
4) Split spheroids every 3-4 days.
   a) To passage cells, collect spheroids in methylcellulose media and dilute in PBS (~3 medium volumes) to reduce the medium's viscosity prior to centrifugation.
5) Centrifuge spheroids at 800g for 15 minutes. Remove methylcellulose media and PBS from the spheroid pellets.
6) Add Accutase to the pellets to dissociate the spheroids into single cells.
   a) In this protocol, 10 mL of Accutase per 100 million cells in spheroids were used, which were incubated for ~30 minutes until spheroids were fully dissociated into single cells. Single cells were then re-seeded at the starting density in step 3).

References

[1] K. Han *et al.*, "CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities," *Nature*, vol. 580, no. 7801, pp. 136–141, Apr. 2020, doi: 10.1038/s41586-020-2099-x.

10.4. *Lentiviral infection protocol*
Small scale infection of mammalian cells with Lentivirus: Adherent Cells Version

Materials:
- ThermoFisher cell culture numbers for adherent cells:
- https://www.thermofisher.com/us/en/home/references/gibco-cell-culture-basics/cell-culture-protocols/cell-culture-useful-numbers.html

Infection Procedure:

Cell Line	# of cells (24 Well)
293T	50,000
HeLa	20,000
HAP1	20,000

1) Count and plate the # of cells listed above for each infection in a well of a 24 well plate. (If you want to plate the cells the day before, plate half as many as listed above)
2) Sterile filter with 1 0.45nM filter. Add 1-2 mL of virus(es) to each well and leave to incubate for 24 hours at 37C.
3) After incubating, aspirate the viral media from each well. Add 1 mL of proper media to the cells.
4) 48-72 hours later, the cells should be ready for analysis by fluorescence or selection with antibiotic.

References

[1] "Small scale infection of mammalian cells with Lentivirus: Adherent Cells Version · Benchling." Accessed: Oct. 05, 2024. [Online]. Available: https://benchling.com/uw_hesslab/f/lib_jUyOwxBE-tissue-culture-protocols/prt_Sdt7mJ5N-small-scale-infection-of-mammalian-cells-with-lentivirus-adherent-cells-version/edit

10.5. *High-throughput CRISPR screen protocol*

This protocol was originally written for use with HuH7 and U-2 OS cells. However, the protocol steps to test dose-response cytotoxicity can be applied to any cell type, including A549 cells which will be used for our project.

Materials: See "key resources" table in protocol [1] for a more detailed description of necessary reagents for the CRISPR screening process.

Procedure:

10.5.a. *Generate Cas9-Expressing Cells*

The Cas9 endonuclease and targeting sgRNAs can be introduced together or separately through lentiviral transduction. This integrates Cas9 and sgRNAs non-specifically into the genome, which is appropriate for almost all CRISPR screens in immortalized cells. Through this protocol, constitutive Cas9 expression is induced through lentiviral transduction. Cas9 is then stably expressed and remains active throughout the screening process.

1) Plate 300,000 HEK293T cells into one well of a 6-well culture plate in 1 mL DMEM + 10% FBS such that they are at ~50% confluence 24 h later.
2) After 24 h, transfect HEK293T cells with Mirus LT1 transfection reagent, 500 ng 3rd generation lentiviral packaging vector mix (equal parts pMDLg/pRRE [Addgene # 12251], pRSV-Rev [Addgene # 12253], and pMV2.g [Addgene # 12259]), and 500 ng pLenti-Cas9-blast (Addgene # 52962) at a 3:1 Mirus:DNA ratio. Follow Mirus Bio's "TransIT-LT1 Full Transfection Protocol" [2].

   > **Critical:** To ensure sufficient viral titers are reached, all library and packaging plasmids should be endotoxin-free and the packaging HEK293T cells need to be healthy prior to transfection.

3) Incubate cells for 72 h.
4) After 72 h, collect viral supernatant through a 0.45 μm filter. Use immediately or store at 4°C for up to one week or −80°C for up to six months.

   > **Critical:** When working with lentivirus, bleach all media and supplies and turn on ultraviolet light in the biosafety cabinet for thirty minutes to inactivate viral particles.

5) Plate 100,000 HuH7 cells into two wells of a 6-well tissue culture plate in DMEM + 10% FBS such that cells are at ~80% confluence 24 h later.

6) After 24 h, introduce 0.5 mL fresh DMEM + 10% FBS and 0.5 mL pLenti-Cas9-blast lentivirus-containing medium to the cells in one well with 8 µg/mL polybrene. Incubate for 24 h.

> **Note:** Keep one well uninfected as a control for the antibiotic selection.

7) After 24 h, remove viral media and replace with DMEM + 10% FBS.
   a) Expand cells for 24 h and then begin antibiotic selection with 4 µg/mL blasticidin.

   > **Note:** With the amount of lentivirus added in step 6, ~30%–50% of cells should be infected. Cells can therefore start selection at high confluency and not overgrow the plate.

   b) Replace the selection media every 3–4 days and split cells as necessary until all control cells have died.

   > **Note:** The concentration of selection antibiotic is dependent on the cell line. This concentration should be determined in advance with antibiotic kill curves.

8) Once all control cells have died, replace media for Cas9 cells with fresh DMEM + 10% FBS without antibiotics to allow cells to recover. These are now your "Cas9" cells.

> **Note:** Cas9 pools or clonal cells can be used for CRISPR screening. To avoid clonal bias from the genetic background, this protocol calls for screening pools of Cas9 cells and does not select monoclonal cells.

9) Validate Cas9 expression by Western blot.
10) Freeze cells at −80°C and store in liquid nitrogen.

> **Note:** It is useful to expand these cells and store in excess since they can be used for subsequent screens or individual gene knockouts.

> **Note:** After introduction into cells, it is important to make sure that Cas9 is active (steps 11-16). To test Cas9 activity, independently infect cells with a lentiviral plasmid encoding: 1. mCherry plus a non-targeting sgRNA (control) and 2. mCherry plus an mCherry-targeting sgRNA. Employ flow cytometry to measure mCherry expression. Cells expressing active Cas9 will cleave the mCherry DNA and appear as an mCherry negative population. Conversely, cells lacking active Cas9 will fail to cleave the mCherry DNA and appear as an mCherry positive population. Due to the long half-life of mCherry, it may take up to 1–2 weeks to distinguish the active Cas9 (e.g., mCherry-negative) cells.

11) Repeat steps 1–4 to make lentiviral media containing a control sgRNA or mCherry-targeting sgRNA (see "key resources" table [1] for sequences) cloned into pMCB320 lentiviral vector (Addgene # 89359).

12) Plate 100,000 HuH7 Cas9 cells into three wells of a 6-well plate in DMEM + 10% FBS so that cells reach ~80% confluence 24 h later.

13) After 24 h, introduce viral media containing the control sgRNA or the mCherry-targeting sgRNA cloned into the pMCB320 lentiviral vector with 8 μg/mL polybrene to two of the wells. Incubate for 24 h.

14) After 24 h, remove viral media and replace with DMEM + 10% FBS. Expand cells for 48 h and then begin antibiotic selection with 2 μg/mL puromycin (see note above on antibiotic concentrations). Replace the selection media every 3–4 days until all control cells have died.

15) Once all control cells have died, replace media with fresh DMEM + 10% FBS without antibiotics to allow cells to recover.

16) Measure mCherry fluorescence by flow cytometry to validate Cas9 activity.

10.5.b. *Dose Response Analysis to Determine Concentration of Cytotoxic Compounds*

An optimal concentration of your choice compound to induce cell death is crucial to achieving the maximum dynamic range of the screen readout. For a drug-resistance screen, a sub-lethal concentration of drug that causes very modest cell death (~5%) in 24-48 h should be determined. Presumably, the depletion of a drug resistance factor will lead to a substantial increase in the sensitivity to the drug, leading to a depletion of the sgRNA over time. For a drug-sensitivity screen, an initial drug concentration that causes ~50% cell death should be determined. However, as pools of surviving cells from the initial selection will become resistant to cell death induced by the drug, a slightly higher concentration may be required for each subsequent treatment cycle to achieve ~50% death.

> **Note:** This is a specific example for identifying ferroptosis resistance factors using known ferroptosis inducing compounds. However, this protocol can be extrapolated to any treatment or condition that provides a selective pressure on cell viability.

17) On day 0, seed ~5,000 U-2 OS cells in each well of a 96-well plate such that the final volume per well is 200 μL.

18) On day 1, aspirate the media from the 96 well-plate and replace it with 100 μL fresh media.

19) Prepare a 2× final solution of the compound at varying concentrations by serial dilution in media containing 60 nM SYTOX Green Dead Cell Stain.

Note: 8–12 different concentrations are recommended to ensure that the optimum concentration is within the standard curve. It is recommended to begin with a 10-point, 5-fold dilution series.

20) Slowly add 100 µL compound containing media back to each well so that the final volume of media in each well is 200 µL with 30 nM SYTOX Green Dead Cell Stain.
21) Monitor cell death using an Incucyte Live-Cell Analysis System (Essen Biosciences), taking images every 2 h for 24–48 h total. Dead cells will be SYTOX green-positive.
22) On day 2 or 3, determine the percentage of cell death by dividing the number of dead cells (SYTOX green-positive) by the total number of cells (visualized by phase imaging).

Note: Due to some limitations of the Incucyte system and the dramatic difference in cell morphology, thresholding and automatically counting total cell number using phase images can sometimes be difficult and inaccurate. Generating a cell line that stably expresses mCherry or using a genetically encoded live-cell nuclear marker (e.g., Incucyte Nuclight reagents) greatly improves the accuracy of the counting for live cells.

Note: If an Incucyte Live-Cell Analysis System is not available, a CellTiter-Glo 2.0 Cell Viability Assay can be used to determine the sub-lethal dose of the drug.

23) Choose a concentration of drug that results in ~5% cell death. Use this concentration for the CRISPR screen.

10.5.c. <u>Determine the Dynamic Range for Fluorescence-Based Assays</u>

The confidence of screen results depends on the dynamic range of the fluorescence reporter. A greater distance between the high and low fluorescence intensity bins will result in less biological noise and will increase the confidence of positive results and reduce the occurrence of false positives and negatives [3]. When possible, it is useful to determine the dynamic range of a cell population using a positive control prior to screening to ensure that cells with altered phenotypes can be accurately sorted by FACS.

Note: Fluorescence can arise from a fluorescent reporter protein or a fluorescent dye. To obtain the highest dynamic range from a reporter protein, it may be useful to sort cells to obtain a population with uniform fluorescence levels. For fluorescent dyes, test multiple concentrations and incubation times.

Note: It is important to establish the timeframe and treatment conditions before performing the screen itself. For example, it may take several days for a genetic perturbation or drug to produce a measurable effect on a fluorescent reporter. Cells may also need to be differentiated or pretreated with drugs or nutrients. Therefore, optimize conditions and establish a timeline for seeding cells, inducing genetic perturbations,

differentiating (if applicable), and treating cells, and carry it over to the screen to yield the most robust results.

24) Choose a positive control gene (if possible) that is known to influence levels of the fluorescent reporter. Generate a knockout cell line or treat cells with a drug targeting the positive control protein. Confirm that the expected increase or decrease in fluorescence is detectable by flow cytometry.

25) Measure fluorescence by flow cytometry to validate that a change in fluorescence is detected and to determine the dynamic range of your assay.

   a) In this example, HuH7 cells were treated with 1 μg/mL triacsin C or 100 μM oleic acid to deplete or increase neutral lipid storage, respectively. Cells were treated with 1 μg/mL BODIPY 493/503 to label neutral lipids and fluorescence was measured by flow cytometry. The 10× decrease and 5× increase in fluorescence intensity will be the target dynamic range of fluorescence for this CRISPR screen.

   Note: Fluorescence intensity can diminish over time. Incubate cells on ice for multiple hours (as long as the FACS sort will be) and check that fluorescence does not change during sorting. We have not found this to be an issue with GFP-based reporters. If necessary, cells can be fixed prior to FACS to ensure fluorescent marker stability over time.

   Note: In some cases, there are no drugs or known regulators to manipulate or validate the system. In the absence of a positive control to validate the fluorescence reporter, it is possible to move directly to the screen.

10.5.d. *Prepare sgRNA Library*

Many genome-scale and small-scale libraries are deposited on Addgene. This protocol used the Bassik Human CRISPR Knockout Library (Addgene # 101926-101934), which is composed of 9 sublibraries, or the custom Human Lipid Droplet and Metabolism Library (Addgene # 191535). Each sgRNA library will need to be amplified and packaged into lentivirus. Alternatively, pre-packaged lentivirus can be purchased directly from Addgene.

26) Follow the Bassik Lab's "Liquid Culture Library Plasmid Re-amp Protocol" [4].
27) Measure DNA concentration using the Qubit dsDNA HS Assay.

10.5.e. *Preparing for Deep Sequencing*

To identify the sgRNAs present in each cell population, genomic DNA (gDNA) is extracted from frozen cell pellets and guide sequences are amplified by PCR.

> **Note:** This protocol modifies the above protocol for increased yield. For the DNA precipitation step, increase the spin time if centrifuging at a slower speed to fully precipitate DNA. Elute with Qiagen Buffer EB (10 mM Tris-Cl, pH 8.5; Cat # 19086) instead of Buffer AE. Spin at 4,500 × g for 5 min. Elute 2–3 times with new Buffer EB each time (do not reload eluate).

28) Extract gDNA from cell pellets using Qiagen QIAamp DNA Blood Midi Kit (Cat # 51183) according to the manufacturer's instructions [5].
29) Measure the gDNA concentration by nanodrop. 100 μg gDNA per 20×10^6 cells are typically obtained.
30) Amplify the integrated sgRNA (PCR1) with the following reagents and reaction program:

> **Critical:** To make sure the diversity and coverage of sgRNAs is not lost during PCR1, multiple 100 μL PCR reactions are required for screen preparation. Empirically, we recommend 1 PCR reaction for every 2,500 sgRNA in the library (e.g., For a customized library that has 25,000 sgRNAs, at least 10 PCR reactions are needed, and therefore a minimum of 100 μg gDNA is required).

> **Note:** Although this protocol calls for 10 μg of genomic DNA per 100 μL PCR1 reaction, DNA input can be decreased to 5 μg or less if necessary.

Table 1. PCR1 reaction master mix reagents and volumes.

Reagent	Volume (μL)
gDNA template (10 μg)	x
Herculase II polymerase	2
oMCB_1562 (100 μM)	1
oMCB_1563 (100 μM)	1
5× Herculase buffer	20
dNTPs (100 nM)∗	1
ddH2O	75-x

∗25 nM per dNTP.

Table 2: PCR1 cycling conditions.

Steps	Temperature	Time	Cycles
Initial Denaturation	98°C	2 min	1
Denaturation	98°C	30 s	18
Annealing	59.1°C	30 s	
Extension	72°C	45 s	
Final Extension	72°C	3 min	1
Hold	4°C	∞	

Note: As the amount of genomic DNA collected from cell samples can be limited, especially for FACS-based screens, it is highly recommended to run a single (or "pilot") PCR1 to ensure all conditions are correct and yield an amplified fragment.

31) Pool and mix all amplicons of the PCRs from the same gDNA sample. Add Illumina sequencing indexes with the following reagents and reaction program:

Table 3: PCR2 reaction master mix reagents and volumes.

Reagent	Volume (μL)
PCR1 Product	5
Herculase II polymerase	2
oMCB_1440 (100 μM)	0.8
oMCB_1439 (100 μM)	0.8
5× Herculase buffer	20
dNTPs (100 nM)*	2
ddH2O	69.4

Table 4: PCR2 cycling conditions.

Steps	Temperature	Time	Cycles
Initial Denaturation	98°C	2 min	1
Denaturation	98°C	30 s	20
Annealing	59.1°C	30 s	

Extension	72°C	45 s	
Final Extension	72°C	3 min	1
Hold	4°C	∞	

Note: Though PCR1 uses 18 cycles, it was empirically determined that 20 cycles for PCR2 resulted in the best signal-to-noise ratio.

Note: Selecting index adapters with diverse sequences for pooled libraries is CRITICAL: for successful sequencing and data analysis. For information on how to optimize the color balance of the index adapters see the "Index Adapters Pooling Guide" published by Illumina.

Note: Only one 100 μL PCR2 reaction is sufficient to achieve sequencing depth.

32) Load PCR products onto 2% TBE-agarose gel.
33) Run the sample at 120 V for 50 min. Excise the brightest band.

> **Note:** The size of the band is expected to be 280 bp but may run higher due to overloading of the gel.

34) Purify DNA products using QiaQuick Gel Extraction Kit (Cat # 28706) according to the manufacturer's instructions [6].

> **Note:** We slightly modified this protocol for increased yield. When dissolving the gel, add 4 volumes Buffer QG instead of 3. For the DNA precipitation step, add 3 M sodium acetate pH 5.2 at a 1:100 ratio. For the wash step, wash with Buffer PE two times instead of once. Elute DNA in Buffer EB, not water.

35) Check DNA concentration by Qubit dsDNA HS Assay. We typically obtain 30 ng/mL DNA.
36) Verify DNA quality using a fragment analyzer. DNA fragments should run as a single band at ~300 bp.
37) If the DNA runs as a single band at ~300 bp without contamination at other sizes, pool equal amounts of DNA from each screen sample so that the final concentration is 3 nM. Send the pooled library for deep sequencing.

> **Note:** The molecular weight of the DNA can be calculated based on the nucleotide sequence.

a) 50 μL of the pooled library at 3 nM and 30 μL of the Bassik custom sequencing Illumina sequencing primer (oMCB1672_new10gCRKO) at 100 μM are typically sent. Both are sent in Qiagen EB (10 mM Tris, pH 8.5).

38) Analyze deep sequencing data using casTLE.

References

[1] A. J. Mathiowetz, M. A. Roberts, D. W. Morgens, J. A. Olzmann, and Z. Li, "Protocol for performing pooled CRISPR-Cas9 loss-of-function screens," *STAR Protoc.*, vol. 4, no. 2, p. 102201, Mar. 2023, doi: 10.1016/j.xpro.2023.102201.

[2] "Transit-LT1 transfection reagent – 0.4 mL," Mirus Bio, Accessed: Oct. 10, 2024. [Online]. Available: https://www.mirusbio.com/product/transit-lt1-transfection-reagent-0-4-ml/

[3] T. Nagy and M. Kampmann, "Crispulator: A discrete simulation tool for pooled genetic screens," *BMC Bioinformatics*, vol. 18, no. 1, Jul. 2017. doi:10.1186/s12859-017-1759-9.

[4] A. Truong, Liquid culture library plasmid re-amp Protocol, Accessed: Oct. 10, 2024 [Online]. Available:
https://media.addgene.org/cms/filer_public/05/f3/05f37d31-3984-4531-9a27-6d591a4b5c5e/liquid_culture_library_plasmid_reamp_bassik.pdf.

[5] QIAamp® DNA BLOOD MIDI/maxi handbook, Accessed: Oct. 10, 2024 [Online]. Available:
https://www.qiagen.com/us/resources/download.aspx?id=bf32146a-77fd-40c2-8743-c28974f7935b&lang=en.

[6] QIAquick® Spin Handbook, Accessed: Oct. 10, 2024. [Online]. Available:
https://www.qiagen.com/ye/resources/download.aspx?id=a9de0fd4-e405-4bb7-b3a0-a74b336d613e&lang=en.

10.6.   *qPCR Testing Protocol*

Materials: RNA Quick Extract
(https://biosearchtech.a.bigcontent.io/v1/static/manual_QER090150_QuickExtract-RNA)

Procedure:

10.6.a. *RNA Extraction*
1) Harvest 10^3-10^6 cells (at least 10^5 recommended). Pellet cells at 1000g for 5 minutes at 4°C. Remove supernatant.

> *Note: You can use half the cells if you half the amount of RNA quick extract you use in Step 3.*

2) Optional: Wash cells in PBS, by adding 500 µL of PBS and centrifuge for 5 minutes at 1000g and 4 minutes. Aspirate supernatant.
3) Add 100 uL of ice-cold RNA quick extract. Vortex mix for 1 minute.
4) This mixture can be stored at -70°C.

10.6.b. *cDNA Synthesis*
5) This protocol is for 20µL/2µg of RNA protocol. Prepare in PCR tubes:

RNA (2µg)   x
Oligo dT (0.5µg/µL)   2
H₂O   8-x

Note: If using a transcript specific primer, Oligo concentration should be 0.5-1 μM in final RT reaction. I usually use 2μL of 10μM stock.

6) Heat sample at 70°C for 5 minutes. Place heated sample on ice for 5 minutes.
7) Add 10µL of following mix:

5X AMV RT Buffer   4
10mM dNTPs   1
RNAsin   0.25
AMV RT   0.75
H₂O   4

8) Incubate at 42°C for 2 hours.
9) If going into a PCR, add 50 uL of Milli-Q-H2O and proceed to set up qPCR reaction.

10.6.c. *Setting up qPCR: SYBR Green Method*

10) **Designing the primers***: If you do not have preset primer pairs for qPCR, you can get them from literature or you can also gather them from (https://www.idtdna.com/site/order/qpcr/predesignedassay).

11) **Designing the experiment***: For these experiments, you require a housekeeping gene as a loading control in addition to your genes of interest. We have designed primers for GAPDH and RPL19 (see below).

Table 1: qPCR Primers designed by Hess Lab.

Name	Sequence
oGH1850 hGAPDH qPCR For	agccacatcgctcagacac
oGH1851 hGAPDH qPCR Rev	gcccaatacgaccaaatcc
hRPL19 For	ATGTATCACAGCCTGTACCTG
hRPL19 Rev	TTCTTGGTCTCTTCCTCCTTG

12) You will need the following samples:

Experimental sample is measured at 1:10 dilution in triplicate – with designed primers.

Experimental sample is measured at 1:10 dilution in triplicate – housekeeping primers. Primer curve of control template to be done (1 well each dilution) done in duplicate for each primer set consisting of:

> No dilution
> 1:5 dilution
> 1:25 dilution
> 1:125 dilution
> 1:625 dilution
> 1:3125 dilution
> Empty sample

13) Set up the Following Master Mix:

Table 2: Master Mix Reagents.

Reagent	1X	25X
H_2O	14.32	358
5x AMV Buffer	4.4	110
50 mM $MgCl_2$	0.28	7
10mM dNTP	0.4	10
100 µM 5' Primer	0.15	3.75
100 µM 5' Primer	0.15	3.75
10X Sybr Green (in DMSO)	0.2	5
Promega GoTaq Polymerase	0.1	2.5
Total:	20	500

14) Prepare enough of this mix for all experimental samples, all primer curve samples, plus extra.
15) Prepare 1:10 dilution of each sample from cDNA for use as template.
16) Prepare dilution series of control sample for primer curves.
17) Add 20 uL to each well, then add 2 µL sample template (Final reaction volume is 22 µL).
18) Set up the following:

> 95ºC 5 min
> 95ºC 30 s
> 55ºC 30 s
> 72ºC 1 min

75ºC 10 s
Plate read
Go to 2 39 times
72ºC 5 min
Melting curve 70-94°C read every 0.2°C, hold for 10 s between reads

19) **Analysis:**
   a) Get the value with CT or Cq values.
   b) Using these values for the different primer pairs, generate a standard curve (the curve should be linear with the CT values on the axis and logarithmic y-axis for the relative amount of cDNA added.
   c) Using the equation for this curve, you can use the CT values obtained for your experimental samples to interpolate the relative amount of your specific gene and the housekeeping gene.
   d) Using these values, you can determine the change in this ratio for your sample to determine if the expression of your gene has been perturbed.

References:

[1] qPCR Protocol · Benchling, Accessed: Oct. 10, 2024. [Online]. Available: https://benchling.com/uw_hesslab/f/lib_xtPaCTIU-extraction-and-staining-protocols/prt_Va3aG4 Cc-qpcr-protocol/edit.